US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
*
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
DK2270149T3
(da)
|
1999-04-09 |
2016-05-09 |
Kyowa Hakko Kirin Co Ltd |
Fremgangsmåde til at kontrollere aktiviteten af immunologisk funktionelt molekyle.
|
US6693176B1
(en)
*
|
1999-07-23 |
2004-02-17 |
University Of Massachusetts |
Antitumor antibodies, proteins, and uses thereof
|
FR2807767B1
(fr)
*
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
AU2016204535C1
(en)
*
|
2000-04-12 |
2017-02-23 |
Laboratoire Français Du Fractionnement Et Des Biotechnologies |
Anti-D monoclonal antibodies
|
US7598055B2
(en)
|
2000-06-28 |
2009-10-06 |
Glycofi, Inc. |
N-acetylglucosaminyltransferase III expression in lower eukaryotes
|
US20060034830A1
(en)
*
|
2000-06-28 |
2006-02-16 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform
|
US20060024304A1
(en)
*
|
2000-06-28 |
2006-02-02 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform
|
US20060034828A1
(en)
*
|
2000-06-28 |
2006-02-16 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform
|
US8697394B2
(en)
|
2000-06-28 |
2014-04-15 |
Glycofi, Inc. |
Production of modified glycoproteins having multiple antennary structures
|
US20060029604A1
(en)
*
|
2000-06-28 |
2006-02-09 |
Gerngross Tillman U |
Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
|
US7863020B2
(en)
|
2000-06-28 |
2011-01-04 |
Glycofi, Inc. |
Production of sialylated N-glycans in lower eukaryotes
|
US7625756B2
(en)
|
2000-06-28 |
2009-12-01 |
GycoFi, Inc. |
Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells
|
US7449308B2
(en)
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
DK1522590T3
(da)
*
|
2000-06-28 |
2009-12-21 |
Glycofi Inc |
Fremgangsmåde til fremstilling af modificerede glykoproteiner
|
US6946292B2
(en)
*
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
CN102311986B
(zh)
*
|
2000-10-06 |
2015-08-19 |
协和发酵麒麟株式会社 |
产生抗体组合物的细胞
|
EP1355666B1
(en)
|
2000-12-22 |
2012-06-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Use of repulsive guidance molecule (RGM) and its modulators
|
WO2002070672A2
(en)
*
|
2001-03-06 |
2002-09-12 |
The Dow Chemical Company |
Plant cell having animal-type sugar chain adding function
|
US20030157108A1
(en)
*
|
2001-10-25 |
2003-08-21 |
Genentech, Inc. |
Glycoprotein compositions
|
WO2003049704A2
(en)
*
|
2001-12-11 |
2003-06-19 |
University Of Massachusetts |
Antibodies to treat cancer
|
US20040093621A1
(en)
*
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
US8932825B2
(en)
|
2001-12-27 |
2015-01-13 |
Glycofi Inc. |
Method to engineer mammalian-type carbohydrate structures
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US6964784B2
(en)
*
|
2002-03-07 |
2005-11-15 |
Optigenex, Inc. |
Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals
|
WO2003085118A1
(fr)
*
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Procede de production de composition anticorps
|
WO2004022597A1
(ja)
|
2002-09-04 |
2004-03-18 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3の血中可溶化n端ペプチドに対する抗体
|
PL373256A1
(en)
*
|
2002-04-09 |
2005-08-22 |
Kyowa Hakko Kogyo Co, Ltd. |
Cells with modified genome
|
EP1498491A4
(en)
*
|
2002-04-09 |
2006-12-13 |
Kyowa Hakko Kogyo Kk |
METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
|
WO2003085102A1
(fr)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose
|
WO2003084570A1
(fr)
*
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia
|
AU2003236017B2
(en)
*
|
2002-04-09 |
2009-03-26 |
Kyowa Kirin Co., Ltd. |
Drug containing antibody composition
|
FR2844455B1
(fr)
*
|
2002-09-13 |
2007-12-14 |
Lab Francais Du Fractionnement |
Traitement des pathologies echappant a la reponse immune par des anticorps optimises
|
EP2298805A3
(en)
|
2002-09-27 |
2011-04-13 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20040115204A1
(en)
*
|
2002-12-11 |
2004-06-17 |
Fanger Gary R. |
Antibodies to treat cancer
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
US7332299B2
(en)
|
2003-02-20 |
2008-02-19 |
Glycofi, Inc. |
Endomannosidases in the modification of glycoproteins in eukaryotes
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
JP4739954B2
(ja)
|
2003-03-13 |
2011-08-03 |
中外製薬株式会社 |
変異受容体に対するアゴニスト活性を有するリガンド
|
US7790399B2
(en)
*
|
2003-04-03 |
2010-09-07 |
Laboratoire Francais du Fractionnement et des Biotechnolgies (LFB) |
Preparation of human, humanized or chimaeric antibodies or polypeptides having different binding profiles to Fcgamma receptors
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
DE602004028249D1
(de)
*
|
2003-06-18 |
2010-09-02 |
Chugai Pharmaceutical Co Ltd |
Fucosetransporter
|
AU2004256354B2
(en)
|
2003-07-15 |
2011-07-07 |
Chugai Seiyaku Kabushiki Kaisha |
IgM production by transformed cells and methods for quantifying said IgM production
|
FR2858235B1
(fr)
*
|
2003-07-31 |
2006-02-17 |
Lab Francais Du Fractionnement |
Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
|
JP4643450B2
(ja)
|
2003-08-08 |
2011-03-02 |
株式会社ペルセウスプロテオミクス |
癌高発現遺伝子
|
EP1666501A4
(en)
|
2003-08-11 |
2008-12-24 |
Chugai Pharmaceutical Co Ltd |
ANTI-HM1.24 ANTIBODIES WITH MODIFIED SUGAR CHAIN
|
US8399618B2
(en)
|
2004-10-21 |
2013-03-19 |
Xencor, Inc. |
Immunoglobulin insertions, deletions, and substitutions
|
US8883147B2
(en)
|
2004-10-21 |
2014-11-11 |
Xencor, Inc. |
Immunoglobulins insertions, deletions, and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
EP1688437A4
(en)
*
|
2003-10-08 |
2007-09-26 |
Kyowa Hakko Kogyo Kk |
SPECIALLY BINDING ANTIBODY COMPOSITION TO IL-5 RECEPTOR
|
JPWO2005035582A1
(ja)
*
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
Ccr4に特異的に結合する抗体組成物
|
US20050287138A1
(en)
*
|
2003-10-08 |
2005-12-29 |
Kyowa Hakko Kogyo Co., Ltd. |
CCR4-specific antibody composition
|
JPWO2005035586A1
(ja)
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
融合蛋白質組成物
|
US20050226867A1
(en)
*
|
2003-10-08 |
2005-10-13 |
Kyowa Hakko Kogyo Co., Ltd. |
IL-5R-specific antibody composition
|
US7691810B2
(en)
|
2003-10-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Method of producing recombinant antithrombin III composition
|
US20060021071A1
(en)
*
|
2003-10-09 |
2006-01-26 |
Kyowa Hakko Kogyo Co., Ltd. |
Cell in which genome is modified
|
EP1705251A4
(en)
*
|
2003-10-09 |
2009-10-28 |
Kyowa Hakko Kirin Co Ltd |
PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
|
WO2005035740A1
(ja)
*
|
2003-10-09 |
2005-04-21 |
Kyowa Hakko Kogyo Co., Ltd. |
無血清馴化したゲノム改変細胞
|
WO2005035574A1
(ja)
|
2003-10-09 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
IgM高濃度安定化溶液
|
JPWO2005035741A1
(ja)
*
|
2003-10-09 |
2006-12-21 |
協和醗酵工業株式会社 |
ゲノムが改変された細胞
|
LT2348051T
(lt)
|
2003-11-05 |
2019-02-25 |
Roche Glycart Ag |
Cd20 antikūnai su padidintu fc receptoriaus prisijungimo giminingumu ir efektorine funkcija
|
WO2005053742A1
(ja)
*
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
JP2007512846A
(ja)
|
2003-12-04 |
2007-05-24 |
ゼンコー・インコーポレイテッド |
増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
|
CN102838675B
(zh)
|
2003-12-10 |
2014-07-30 |
梅达雷克斯有限责任公司 |
Ip-10抗体及其用途
|
WO2005059106A2
(en)
|
2003-12-10 |
2005-06-30 |
Medarex, Inc. |
Interferon alpha antibodies and their uses
|
US20080025913A1
(en)
*
|
2003-12-15 |
2008-01-31 |
Bowdish Katherine S |
Novel Anti-Dc-Sign Antibodies
|
ATE393169T1
(de)
|
2003-12-30 |
2008-05-15 |
Merck Patent Gmbh |
Il-7-fusionsproteine mit antikörperportionen, deren herstellung und deren verwendung
|
JP2005224240A
(ja)
*
|
2004-01-13 |
2005-08-25 |
Kyowa Hakko Kogyo Co Ltd |
ノックアウト非ヒト動物から樹立された不死化細胞株
|
PL1706428T3
(pl)
|
2004-01-22 |
2010-02-26 |
Merck Patent Gmbh |
Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
|
CA2558635A1
(en)
*
|
2004-03-17 |
2005-09-29 |
Glycofi, Inc. |
Method of engineering a cytidine monophosphate-sialic acid synthetic pathway in fungi and yeast
|
WO2005092925A2
(en)
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
DOP2005000108A
(es)
*
|
2004-06-04 |
2007-06-15 |
Genentech Inc |
Method for treating lupus
|
KR20150092374A
(ko)
*
|
2004-06-04 |
2015-08-12 |
제넨테크, 인크. |
다발성 경화증의 치료 방법
|
PL2662390T3
(pl)
|
2004-06-21 |
2017-12-29 |
E. R. Squibb & Sons, L.L.C. |
Antyciała receptora interferonu alfa I oraz ich zastosowania
|
WO2006006693A1
(ja)
|
2004-07-09 |
2006-01-19 |
Chugai Seiyaku Kabushiki Kaisha |
抗グリピカン3抗体
|
WO2006005367A1
(en)
|
2004-07-14 |
2006-01-19 |
Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag |
N-glycosylated antibody
|
EP1919950A1
(en)
|
2004-07-15 |
2008-05-14 |
Xencor, Inc. |
Optimized fc variants
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
CN101014367B
(zh)
|
2004-08-24 |
2012-07-04 |
中外制药株式会社 |
使用抗磷脂酰肌醇蛋白聚糖-3抗体的辅助疗法
|
EP1812060A2
(en)
|
2004-10-05 |
2007-08-01 |
Genentech, Inc. |
Method for treating vasculitis
|
CA2585196C
(en)
*
|
2004-10-26 |
2015-01-06 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-glypican 3 antibody having modified sugar chain
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
JP4652414B2
(ja)
|
2004-11-12 |
2011-03-16 |
ゼンコー・インコーポレイテッド |
FcRnとの変化した結合を有するFc変異体
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
EP2208783A1
(en)
|
2004-12-22 |
2010-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
|
ES2755976T3
(es)
|
2005-02-07 |
2020-04-24 |
Roche Glycart Ag |
Moléculas de unión a antígeno que se unen a EGFR, vectores que las codifican y usos de las mismas
|
PL1853718T3
(pl)
|
2005-02-15 |
2016-01-29 |
Univ Duke |
Przeciwciała anty-CD19 i zastosowania w onkologii
|
NZ560414A
(en)
*
|
2005-02-18 |
2011-04-29 |
Medarex Inc |
Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues
|
EP2551282A3
(en)
|
2005-03-23 |
2013-02-13 |
Genmab A/S |
Antibodies against CD38 for treatment of multiple myeloma
|
EP1865981A2
(en)
|
2005-04-07 |
2007-12-19 |
Chiron Corporation |
Cacna1e in cancer diagnosis, detection and treatment
|
WO2006110585A2
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
Cancer-related genes (prlr)
|
ES2971647T3
(es)
|
2005-04-15 |
2024-06-06 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
EP1885755A4
(en)
|
2005-05-05 |
2009-07-29 |
Univ Duke |
TREATMENTS OF AUTOIMMUNE DISEASES BY ANTI-CD19 ANTIBODIES
|
PT2161336E
(pt)
|
2005-05-09 |
2013-10-03 |
Ono Pharmaceutical Co |
Anticorpos monoclonais humanos para morte programada 1 (pd-1) e métodos de tratamento do cancro utilizando anticorpos anti- pd-1 sozinhos ou em combinação com outros agentes imunoterapêuticos¿
|
AU2006251647A1
(en)
|
2005-05-20 |
2006-11-30 |
Genentech, Inc. |
Pretreatment of a biological sample from an autoimmune disease subject
|
KR20080025174A
(ko)
|
2005-06-23 |
2008-03-19 |
메디뮨 인코포레이티드 |
응집 및 단편화 프로파일이 최적화된 항체 제제
|
BRPI0611714A2
(pt)
|
2005-06-30 |
2009-01-13 |
Abbott Lab |
proteÍnas de ligaÇço a il-12/p40
|
KR101607288B1
(ko)
|
2005-07-01 |
2016-04-05 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
WO2007021841A2
(en)
|
2005-08-10 |
2007-02-22 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant fc regions and methods of using same
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP1928506A4
(en)
|
2005-08-19 |
2009-10-21 |
Abbott Lab |
IMMUNOGLOBULIN HAVING TWO VARIABLE DOMAINS AND USES THEREOF
|
EP2500355A3
(en)
|
2005-08-19 |
2012-10-24 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
US20070071745A1
(en)
|
2005-08-26 |
2007-03-29 |
Pablo Umana |
Modified antigen binding molecules with altered cell signaling activity
|
JP2009508476A
(ja)
*
|
2005-08-31 |
2009-03-05 |
セントカー・インコーポレーテツド |
高められたエフェクター機能をもつ抗体定常領域の製造用の宿主細胞株
|
AU2006287173A1
(en)
*
|
2005-09-02 |
2007-03-08 |
Glycofi, Inc |
Immunoglobulins comprising predominantly a GICNAcMan3GIcNAc2 glycoform
|
CA2620713A1
(en)
*
|
2005-09-09 |
2007-03-15 |
Glycofi, Inc. |
Immunoglobulin comprising predominantly a man7glcnac2, man8glcnac2 glycoform
|
EP1928905B1
(de)
|
2005-09-30 |
2015-04-15 |
AbbVie Deutschland GmbH & Co KG |
Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
WO2007044616A2
(en)
|
2005-10-06 |
2007-04-19 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
US20070087005A1
(en)
|
2005-10-14 |
2007-04-19 |
Lazar Gregory A |
Anti-glypican-3 antibody
|
CN101331228B
(zh)
|
2005-10-18 |
2013-07-17 |
独立行政法人农业生物资源研究所 |
产生抗体的转基因家蚕及其制备方法
|
US7700321B2
(en)
|
2005-10-21 |
2010-04-20 |
Genzyme Corporation |
Antibody-based therapeutics with enhanced ADCC activity
|
JP5006330B2
(ja)
|
2005-10-21 |
2012-08-22 |
ノバルティス アーゲー |
Il13に対するヒト抗体および治療的使用
|
FR2892724B1
(fr)
*
|
2005-11-02 |
2008-01-04 |
Lab Francais Du Fractionnement |
Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
|
AU2006312148B2
(en)
*
|
2005-11-07 |
2012-04-12 |
The Rockefeller University |
Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
AU2006319358B2
(en)
|
2005-11-30 |
2012-01-19 |
AbbVie Deutschland GmbH & Co. KG |
Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
|
KR20140087058A
(ko)
|
2005-11-30 |
2014-07-08 |
애브비 인코포레이티드 |
아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
|
EP1954719A2
(en)
|
2005-12-02 |
2008-08-13 |
Genentech Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
|
DK1960434T3
(da)
|
2005-12-08 |
2012-10-15 |
Medarex Inc |
Monoklonale, humane antistoffer mod Fucosyl-GM1 og fremgangsmåder til anvendelse af anti-Fucosyl-GM1
|
EP1966238B1
(en)
|
2005-12-30 |
2012-04-25 |
Merck Patent GmbH |
Interleukin-12p40 variants with improved stability
|
WO2007076950A1
(en)
|
2005-12-30 |
2007-07-12 |
Merck Patent Gmbh |
Anti-cd19 antibodies with reduced immunogenicity
|
PL1977241T3
(pl)
*
|
2006-01-04 |
2011-02-28 |
Novartis Ag |
Badanie cytotoksyczności komórkowej zależnej od przeciwciał
|
US8101365B2
(en)
|
2006-01-05 |
2012-01-24 |
Genentech, Inc. |
Anti-EphB4 antibodies and methods using same
|
US20090060921A1
(en)
*
|
2006-01-17 |
2009-03-05 |
Biolex Therapeutics, Inc. |
Glycan-optimized anti-cd20 antibodies
|
US8716557B2
(en)
|
2006-01-17 |
2014-05-06 |
Synthon Biopharmaceuticals B.V. |
Compositions and methods for inhibition of fucosyltransferase and xylosyltransferase expression in plants
|
BRPI0707446A2
(pt)
|
2006-02-02 |
2011-05-03 |
Allergan Inc |
composições e métodos para o tratamento de doença oftálmica
|
EP2540741A1
(en)
|
2006-03-06 |
2013-01-02 |
Aeres Biomedical Limited |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
AU2007227224A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
US20080014203A1
(en)
*
|
2006-04-11 |
2008-01-17 |
Silke Hansen |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
US7846724B2
(en)
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
DK2446904T3
(da)
|
2006-05-30 |
2015-07-27 |
Genentech Inc |
Anti-CD22-antistoffer, deres immunkonjugater og anvendelser deraf
|
BRPI0710411A2
(pt)
*
|
2006-06-06 |
2012-04-10 |
Genentch Inc Empresa Americana |
Métodos para tratar um tumor, para tratar uma condição patológica associada à angiogênese, para estimular a proliferação celular endotelial, para reduzir ou inibir a diferenciação celular endotelial, para reduzir ou inibir o desenvolvimento arterial, para reduzir ou inibir a perfusão vascular tumoral para aumentar a eficácia de um agente anti-angiogênico, usos de um antagonista de dll4 e uso de um agonisra de dll4
|
BRPI0710413A2
(pt)
|
2006-06-06 |
2011-08-23 |
Genentech Inc |
anticorpos anti-dll4, isolados, polinucleotìdeo, vetor, célular hospedeira, método para produção de um anticorpo anti-dll4, método para produção de um imunoconjugado anti-dll4, método para a detecção de dll4, metodo para diagnosticar um distúrbio, composições, método para tratar um tumor, cáncer e/ou disturbio da proliferação celular e método para melhorar a eficácia de um agente anti-angiogênico
|
EP1878747A1
(en)
|
2006-07-11 |
2008-01-16 |
greenovation Biotech GmbH |
Glyco-engineered antibodies
|
ES2612383T3
(es)
|
2006-07-19 |
2017-05-16 |
The Trustees Of The University Of Pennsylvania |
WSX-1/IL-27 como una diana para respuestas antiinflamatorias
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
EP2050466B1
(en)
|
2006-08-14 |
2015-10-28 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
|
CA2658557C
(en)
|
2006-08-14 |
2015-12-01 |
Xencor, Inc. |
Optimized antibodies that target cd19
|
EA200970250A1
(ru)
|
2006-09-05 |
2010-02-26 |
Медарекс, Инк. |
Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
|
HUE052220T2
(hu)
|
2006-09-08 |
2021-04-28 |
Abbvie Bahamas Ltd |
Interleukin-13 kötõfehérjék
|
PL2066349T3
(pl)
|
2006-09-08 |
2012-09-28 |
Medimmune Llc |
Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
|
EP2428224B1
(en)
|
2006-09-10 |
2016-12-21 |
Glycotope GmbH |
Use of human cells of myeloid leukaemia origin for expression of antibodies
|
US8394374B2
(en)
|
2006-09-18 |
2013-03-12 |
Xencor, Inc. |
Optimized antibodies that target HM1.24
|
ES2553553T3
(es)
|
2006-10-02 |
2015-12-10 |
E. R. Squibb & Sons, L.L.C. |
Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
|
CL2007002926A1
(es)
|
2006-10-12 |
2008-05-16 |
Genentech Inc |
Anticuerpo antilinfotoxina alfa (lt-alfa); composicion con el anticuerpo; hibridoma pta-7538; acido nucleico codificante del anticuerpo; vector y celula huesped que comprenden el acido nucleico; metodo para inhibir la proliferacion celular activada p
|
NZ601022A
(en)
|
2006-10-12 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Diagnosis and treatment of cancer using anti-ereg antibody
|
WO2008047925A1
(fr)
|
2006-10-20 |
2008-04-24 |
Forerunner Pharma Research Co., Ltd. |
Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif
|
MX2009003938A
(es)
|
2006-10-27 |
2009-04-24 |
Genentech Inc |
Anticuerpos e inmunoconjugados y sus usos.
|
US8618248B2
(en)
|
2006-10-31 |
2013-12-31 |
President And Fellows Of Harvard College |
Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
|
NZ577085A
(en)
|
2006-11-15 |
2012-06-29 |
Medarex Inc |
Human monoclonal antibodies to btla and methods of use
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
US8481683B2
(en)
|
2006-12-01 |
2013-07-09 |
Medarex, Inc. |
Human antibodies that bind CD22 and uses thereof
|
US20080127996A1
(en)
*
|
2006-12-04 |
2008-06-05 |
Weinhold Dennis G |
Method and apparatus to remediate an acid and/or liquid spill
|
CL2007003622A1
(es)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
|
WO2008074004A2
(en)
|
2006-12-14 |
2008-06-19 |
Medarex, Inc. |
Human antibodies that bind cd70 and uses thereof
|
AU2007332473B2
(en)
|
2006-12-14 |
2012-09-27 |
Forerunner Pharma Research Co., Ltd. |
Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
|
JPWO2008090960A1
(ja)
|
2007-01-24 |
2010-05-20 |
協和発酵キリン株式会社 |
ガングリオシドgm2に特異的に結合する遺伝子組換え抗体組成物
|
AU2008216495A1
(en)
|
2007-02-09 |
2008-08-21 |
Genentech, Inc. |
Anti-Robo4 antibodies and uses therefor
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
DK2447719T3
(da)
|
2007-02-26 |
2016-10-10 |
Oxford Biotherapeutics Ltd |
Proteiner
|
EP2124952A2
(en)
|
2007-02-27 |
2009-12-02 |
Abbott GmbH & Co. KG |
Method for the treatment of amyloidoses
|
US20100028951A1
(en)
*
|
2007-03-07 |
2010-02-04 |
Stephen Hamilton |
Production of glycoproteins with modified fucosylation
|
CN101641115B
(zh)
|
2007-03-08 |
2013-04-24 |
卡罗拜奥斯制药公司 |
用于实体瘤治疗的EphA3抗体
|
JP5575636B2
(ja)
|
2007-05-07 |
2014-08-20 |
メディミューン,エルエルシー |
抗icos抗体ならびに、腫瘍、移植および自己免疫疾患の治療におけるその使用
|
PT2068927E
(pt)
|
2007-05-14 |
2016-02-10 |
Medimmune Llc |
Métodos para reduzir os níveis de eosinófilos
|
EP3392273A1
(en)
|
2007-05-30 |
2018-10-24 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
MX2009013816A
(es)
|
2007-06-21 |
2010-02-24 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos.
|
EP2175016A4
(en)
|
2007-06-25 |
2012-03-28 |
Forerunner Pharma Res Co Ltd |
ANTI-PROMININ-1 ANTIBODIES WITH ADCC ACTIVITY OR CDC ACTIVITY
|
CN101687924A
(zh)
|
2007-07-04 |
2010-03-31 |
株式会社未来创药研究所 |
抗Muc17抗体
|
EP2626371A1
(en)
|
2007-07-31 |
2013-08-14 |
MedImmune, LLC |
Multispecific epitope binding proteins and uses thereof
|
WO2009018411A1
(en)
*
|
2007-07-31 |
2009-02-05 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to human cd20 and method of using thereof
|
US8501907B2
(en)
|
2007-08-10 |
2013-08-06 |
Janssen Biotech, Inc. |
Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
|
ES2537580T3
(es)
|
2007-09-04 |
2015-06-09 |
Compugen Ltd. |
Polipéptidos y polinucleótidos, y usos de los mismos como una diana farmacológica para producir fármacos y agentes biológicos
|
TWI563002B
(en)
|
2007-09-26 |
2016-12-21 |
Chugai Pharmaceutical Co Ltd |
Antibody constant region mutant
|
ES2394471T3
(es)
*
|
2007-09-28 |
2013-02-01 |
Chugai Seiyaku Kabushiki Kaisha |
Anticuerpo Anti-Glipicano 3 que tiene una cinética mejorada en plasma
|
EP2205258B1
(en)
|
2007-09-28 |
2017-05-24 |
Janssen Biotech, Inc. |
Methods and structural conformations of antibody preparations with increased resistance to proteases
|
TWI489993B
(zh)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
骨硬化素(sclerostin)抗體組合物及使用方法
|
CN101951954A
(zh)
|
2007-11-02 |
2011-01-19 |
诺瓦提斯公司 |
调节低密度脂蛋白受体相关蛋白6(lrp6)的分子和方法
|
RU2503460C2
(ru)
|
2007-11-07 |
2014-01-10 |
Дженентек Инк. |
Применение противомикробного полипептида для лечения микробных нарушений
|
CN104109208A
(zh)
|
2007-11-14 |
2014-10-22 |
中外制药株式会社 |
使用抗gpr49抗体的癌症的诊断和治疗
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
CN105001333B
(zh)
|
2007-12-14 |
2019-05-17 |
诺沃—诺迪斯克有限公司 |
抗人nkg2d抗体及其用途
|
KR101620539B1
(ko)
|
2007-12-21 |
2016-05-13 |
메디뮨 리미티드 |
인터루킨-4 수용체 알파(IL-4Rα)에 대한 결합 구성원-173
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
DK2235059T3
(da)
|
2007-12-26 |
2015-03-30 |
Xencor Inc |
Fc-varianter med ændret binding til fcrn
|
EP2241578B1
(en)
|
2008-01-11 |
2016-04-20 |
The University of Tokyo |
Anti-cldn6 antibody
|
MX2010007767A
(es)
|
2008-01-18 |
2010-08-09 |
Medimmune Llc |
Anticuerpos manipulados con cisteina para conjugacion especifica de sitio.
|
DK2240203T3
(da)
|
2008-02-05 |
2014-05-05 |
Pfizer |
Alfa5-beta1-antistoffer og deres anvendelser
|
MX2010008578A
(es)
|
2008-02-08 |
2010-11-10 |
Medimmune Llc |
Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
EP2252631B1
(en)
|
2008-04-02 |
2016-04-13 |
MacroGenics, Inc. |
Bcr-complex-specific antibodies and methods of using same
|
KR101606386B1
(ko)
|
2008-04-02 |
2016-03-25 |
마크로제닉스, 인크. |
Her2/neu-특이적 항체 및 그것의 사용 방법
|
CL2009000647A1
(es)
|
2008-04-04 |
2010-06-04 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
|
CN103251948A
(zh)
|
2008-04-11 |
2013-08-21 |
中外制药株式会社 |
与多个分子的抗原反复结合的抗原结合分子
|
US9758594B2
(en)
|
2008-04-25 |
2017-09-12 |
Kyowa Hakko Kirin Co., Ltd. |
Stable multivalent antibody
|
AU2009241589B2
(en)
|
2008-04-29 |
2013-10-10 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
PL2439212T3
(pl)
|
2008-05-02 |
2017-06-30 |
Novartis Ag |
Ulepszone cząsteczki wiążące na bazie fibronektyny oraz ich zastosowanie
|
BRPI0911758A8
(pt)
|
2008-05-09 |
2017-10-10 |
Abbott Lab |
Anticorpos para receptor de produtos finais de glicação avançada (rage) e utilizações dos mesmos
|
WO2009147781A1
(ja)
|
2008-06-02 |
2009-12-10 |
国立大学法人東京大学 |
抗がん剤
|
EP3002299A1
(en)
|
2008-06-03 |
2016-04-06 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
MX2010013236A
(es)
|
2008-06-03 |
2011-02-24 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
EP2282770B1
(en)
|
2008-06-04 |
2018-03-07 |
MacroGenics, Inc. |
Antibodies with altered binding to fcrn and methods of using same
|
CA2729567C
(en)
|
2008-06-30 |
2018-04-24 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-cd27 antibody
|
KR101054362B1
(ko)
*
|
2008-07-03 |
2011-08-05 |
재단법인 목암생명공학연구소 |
재조합 단백질의 푸코스 함량을 감소시키는 방법
|
MX2010014574A
(es)
|
2008-07-08 |
2011-04-27 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
|
SG192496A1
(en)
|
2008-07-08 |
2013-08-30 |
Abbott Lab |
Prostaglandin e2 binding proteins and uses thereof
|
RU2519089C2
(ru)
|
2008-08-05 |
2014-06-10 |
Торэй Индастриз, Инк. |
Способ обнаружения злокачественных опухолей
|
MY159396A
(en)
|
2008-08-05 |
2016-12-30 |
Novartis Ag |
Compositions and methods for antibodies targeting complement protein c5
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
WO2010018846A1
(ja)
*
|
2008-08-13 |
2010-02-18 |
協和発酵キリン株式会社 |
ガングリオシドgm2に特異的に結合する抗体組成物を含む医薬
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
EP3581588B1
(en)
|
2008-09-17 |
2022-06-15 |
Xencor, Inc. |
Novel compositions and methods for treating ige-mediated disorders
|
CN102264763B
(zh)
|
2008-09-19 |
2016-04-27 |
米迪缪尼有限公司 |
定向于dll4的抗体及其用途
|
EP2340305A1
(en)
*
|
2008-09-26 |
2011-07-06 |
Eureka Therapeutics, Inc. |
Cell lines and proteins with variant glycosylation pattern
|
PE20150682A1
(es)
|
2008-10-14 |
2015-05-20 |
Genentech Inc |
Variantes de inmunoglobulinas y sus usos
|
WO2010056804A1
(en)
|
2008-11-12 |
2010-05-20 |
Medimmune, Llc |
Antibody formulation
|
GB2466025A
(en)
|
2008-12-08 |
2010-06-09 |
Univ Francois Rabelais De Tour |
C3/ITGAM polymorphisms and cancer prognosis
|
WO2010067308A2
(en)
|
2008-12-08 |
2010-06-17 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
MX348166B
(es)
|
2008-12-19 |
2017-06-01 |
Macrogenics Inc |
Diacuerpos covalentes y sus usos.
|
WO2010074049A1
(ja)
|
2008-12-22 |
2010-07-01 |
株式会社 未来創薬研究所 |
抗hs6st2抗体及びその用途
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
JP6039183B2
(ja)
|
2008-12-23 |
2016-12-07 |
ジェネンテック, インコーポレイテッド |
プロテインaに対する結合が変化した免疫グロブリン変異体
|
US9139647B2
(en)
|
2008-12-25 |
2015-09-22 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and treatment of cancer using anti-TM4SF20 antibody
|
CA2748990A1
(en)
|
2008-12-26 |
2010-07-01 |
The University Of Tokyo |
Diagnosis and treatment of cancer using anti-lgr7 antibody
|
PL2374883T3
(pl)
*
|
2008-12-26 |
2017-05-31 |
Kyowa Hakko Kirin Co., Ltd. |
Przeciwciało anty-CD4
|
ES2539045T3
(es)
|
2009-01-19 |
2015-06-25 |
Innate Pharma |
Anticuerpos anti-KIR3D
|
AU2010207552A1
(en)
|
2009-01-21 |
2011-09-01 |
Oxford Biotherapeutics Ltd. |
PTA089 protein
|
US8030026B2
(en)
|
2009-02-24 |
2011-10-04 |
Abbott Laboratories |
Antibodies to troponin I and methods of use thereof
|
EP2772269A3
(en)
|
2009-03-05 |
2015-01-14 |
Abbvie Inc. |
IL-17 binding proteins
|
NZ594682A
(en)
|
2009-03-05 |
2013-06-28 |
Medarex Inc |
Fully human antibodies specific to cadm1
|
CN102405237A
(zh)
|
2009-03-06 |
2012-04-04 |
卡罗拜奥斯制药公司 |
利用EphA3抗体治疗白血病和慢性骨髓增生性疾病
|
US8283162B2
(en)
|
2009-03-10 |
2012-10-09 |
Abbott Laboratories |
Antibodies relating to PIVKAII and uses thereof
|
UA106070C2
(uk)
|
2009-03-20 |
2014-07-25 |
Дженентек, Інк. |
Антитіло, що специфічно зв'язується з egfr і her3
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
WO2010111254A1
(en)
|
2009-03-25 |
2010-09-30 |
Genentech, Inc. |
Novel anti-alpha5beta1 antibodies and uses thereof
|
TWI507205B
(zh)
|
2009-03-25 |
2015-11-11 |
Genentech Inc |
抗fgfr3抗體及使用方法
|
US20100247484A1
(en)
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
PE20120591A1
(es)
|
2009-04-02 |
2012-05-23 |
Roche Glycart Ag |
Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
|
MX2011010169A
(es)
|
2009-04-07 |
2011-10-11 |
Roche Glycart Ag |
Anticuerpos biespecificos anti-erbb-1/anti-c-met.
|
BRPI1012589A2
(pt)
|
2009-04-07 |
2016-03-22 |
Roche Glycart Ag |
anticorpos bi-específicos anti-erbb-3/anti-c-met
|
PL2417156T3
(pl)
|
2009-04-07 |
2015-07-31 |
Roche Glycart Ag |
Trójwartościowe, bispecyficzne przeciwciała
|
KR101690340B1
(ko)
|
2009-04-09 |
2016-12-27 |
다이이찌 산쿄 가부시키가이샤 |
항 Siglec-15 항체
|
ES2571235T3
(es)
|
2009-04-10 |
2016-05-24 |
Kyowa Hakko Kirin Co Ltd |
Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
|
WO2010119691A1
(ja)
|
2009-04-16 |
2010-10-21 |
国立大学法人東京大学 |
抗tmprss11e抗体を用いた癌の診断と治療
|
PT2423228E
(pt)
|
2009-04-20 |
2016-02-26 |
Kyowa Hakko Kirin Co Ltd |
Anticorpo contendo igg2 em que foram introduzidas mutações de aminoácidos
|
CN106188295A
(zh)
|
2009-04-20 |
2016-12-07 |
牛津生物疗法有限公司 |
特异于钙粘素‑17的抗体
|
AU2010230311B9
(en)
|
2009-04-27 |
2012-09-20 |
Novartis Ag |
Composition and methods of use for therapeutic antibodies specific for the IL-12 receptore betal subunit
|
KR101732201B1
(ko)
|
2009-04-27 |
2017-05-02 |
교와 핫꼬 기린 가부시키가이샤 |
혈액 종양 치료를 목적으로 하는 항IL-3Rα 항체
|
LT2424895T
(lt)
|
2009-04-27 |
2017-12-27 |
Novartis Ag |
Kompozicijos ir būdai, skirti raumenų augimo spartinimui
|
KR20120051603A
(ko)
|
2009-05-01 |
2012-05-22 |
고쿠리츠다이가쿠호징 도쿄다이가쿠 |
항카드헤린 항체
|
WO2010131733A1
(ja)
|
2009-05-15 |
2010-11-18 |
中外製薬株式会社 |
抗axl抗体
|
WO2010138184A2
(en)
*
|
2009-05-27 |
2010-12-02 |
Synageva Biopharma Corp. |
Avian derived antibodies
|
JP5719354B2
(ja)
|
2009-05-27 |
2015-05-20 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
三重又は四重特異性抗体
|
WO2010137654A1
(ja)
|
2009-05-29 |
2010-12-02 |
株式会社未来創薬研究所 |
Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物
|
PL2438171T3
(pl)
|
2009-06-02 |
2015-04-30 |
Regeneron Pharma |
Komórki z niedoborem fukozylacji
|
ES2697535T3
(es)
|
2009-06-11 |
2019-01-24 |
Inter Univ Research Institute Corporation Research Organization Of Information And Systems |
Procedimiento para la producción de proteína
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
CN102686610A
(zh)
|
2009-06-18 |
2012-09-19 |
辉瑞公司 |
抗刻缺蛋白-1抗体
|
EP2711018A1
(en)
|
2009-06-22 |
2014-03-26 |
MedImmune, LLC |
Engineered Fc regions for site-specific conjugation
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
CA2769308A1
(en)
|
2009-07-31 |
2011-02-03 |
Genentech, Inc. |
Inhibition of tumor metastasis using bv8- or g-csf-antagonists
|
BR112012007875A2
(pt)
|
2009-07-31 |
2016-11-22 |
Medarex Inc |
anticorpos totalmente humanos para btla
|
CN102597233B
(zh)
|
2009-08-07 |
2014-10-29 |
协和发酵麒麟株式会社 |
人源化抗淀粉样-b寡聚体抗体
|
SG177679A1
(en)
|
2009-08-07 |
2012-02-28 |
Kyowa Hakko Kirin Co Ltd |
Humanized anti-amyloid-b oligomer antibody
|
TWI409079B
(zh)
|
2009-08-14 |
2013-09-21 |
Roche Glycart Ag |
非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法
|
CA2769595A1
(en)
|
2009-08-14 |
2011-02-17 |
Roche Glycart Ag |
Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
|
AU2010285974A1
(en)
|
2009-08-17 |
2012-03-22 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
|
WO2011021146A1
(en)
|
2009-08-20 |
2011-02-24 |
Pfizer Inc. |
Osteopontin antibodies
|
TWI412375B
(zh)
|
2009-08-28 |
2013-10-21 |
Roche Glycart Ag |
人類化抗cdcp1抗體
|
TW201113037A
(en)
|
2009-08-28 |
2011-04-16 |
Hoffmann La Roche |
Antibodies against CDCP1 for the treatment of cancer
|
CN102741293B
(zh)
|
2009-08-31 |
2015-04-01 |
罗切格利卡特公司 |
亲和力成熟的人源化抗cea单克隆抗体
|
PE20121530A1
(es)
|
2009-09-01 |
2012-12-22 |
Abbvie Inc |
Inmunoglobulinas con dominio variable dual
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
CA2772715C
(en)
|
2009-09-02 |
2019-03-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
WO2011034605A2
(en)
|
2009-09-16 |
2011-03-24 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
MX2012003404A
(es)
|
2009-09-22 |
2012-09-12 |
Volker Sandig |
Procedimiento para producir moleculas que contienen estructuras de glicano especializadas.
|
HUE036549T2
(hu)
|
2009-10-07 |
2018-07-30 |
Macrogenics Inc |
A fukozilezés mértékének megváltozása miatt javított effektor funkciót mutató, Fc-régiót tartalmazó polipeptidek, valamint eljárások alkalmazásukra
|
WO2011047083A1
(en)
|
2009-10-13 |
2011-04-21 |
Oxford Biotherapeutics Ltd. |
Antibodies against epha10
|
AU2010313621C1
(en)
|
2009-10-14 |
2015-11-26 |
Humanigen, Inc. |
Antibodies to EphA3
|
US8716450B2
(en)
|
2009-10-15 |
2014-05-06 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
TW201121566A
(en)
|
2009-10-22 |
2011-07-01 |
Genentech Inc |
Anti-hepsin antibodies and methods using same
|
IN2012DN02604A
(da)
|
2009-10-23 |
2015-09-04 |
Millennium Pharm Inc |
|
CN102596995B
(zh)
|
2009-10-26 |
2015-08-12 |
弗·哈夫曼-拉罗切有限公司 |
用于生产糖基化免疫球蛋白的方法
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
WO2011059684A1
(en)
|
2009-10-29 |
2011-05-19 |
Centocor Ortho Biotech Inc. |
Antibody glycosylation variants
|
WO2011051327A2
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Small antibody-like single chain proteins
|
TW201121568A
(en)
|
2009-10-31 |
2011-07-01 |
Abbott Lab |
Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
|
WO2011051466A1
(en)
|
2009-11-02 |
2011-05-05 |
Novartis Ag |
Anti-idiotypic fibronectin-based binding molecules and uses thereof
|
US20120282177A1
(en)
|
2009-11-02 |
2012-11-08 |
Christian Rohlff |
ROR1 as Therapeutic and Diagnostic Target
|
PE20121646A1
(es)
|
2009-11-04 |
2012-12-02 |
Merck Sharp & Dohme |
Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica
|
US20120316071A1
(en)
|
2009-11-04 |
2012-12-13 |
Vaughn Smider |
Methods for affinity maturation-based antibody optimization
|
US8361744B2
(en)
|
2009-11-05 |
2013-01-29 |
Genentech, Inc. |
Methods and composition for secretion of heterologous polypeptides
|
NO2504364T3
(da)
|
2009-11-24 |
2018-01-06 |
|
|
US9428586B2
(en)
|
2009-12-01 |
2016-08-30 |
Compugen Ltd |
Heparanase splice variant
|
DK2510001T3
(da)
|
2009-12-08 |
2016-02-29 |
Abbvie Deutschland |
Monoklonale antistoffer mod rgm a-proteinet til anvendelse til behandling af degeneration af det retinale nervefiberlag
|
EP2509626B1
(en)
|
2009-12-11 |
2016-02-10 |
F.Hoffmann-La Roche Ag |
Anti-vegf-c antibodies and methods using same
|
PE20121616A1
(es)
|
2009-12-22 |
2012-12-05 |
Roche Glycart Ag |
Anticuerpos anti-her3
|
BR112012017164A2
(pt)
|
2009-12-22 |
2019-09-24 |
Novartis Ag |
proteína de fusão de região constante de anticorpo-cd47 tetravalente
|
MY161868A
(en)
|
2009-12-23 |
2017-05-15 |
Genentech Inc |
Anti-bv8 antibodies and uses thereof
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
WO2011092233A1
(en)
|
2010-01-29 |
2011-08-04 |
Novartis Ag |
Yeast mating to produce high-affinity combinations of fibronectin-based binders
|
US9127071B2
(en)
|
2010-01-29 |
2015-09-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-DLL3 antibody
|
WO2011097527A2
(en)
|
2010-02-04 |
2011-08-11 |
Xencor, Inc. |
Immunoprotection of therapeutic moieties using enhanced fc regions
|
CA2789125A1
(en)
|
2010-02-10 |
2011-08-18 |
Novartis Ag |
Methods and compounds for muscle growth
|
MX341687B
(es)
|
2010-02-10 |
2016-08-30 |
Immunogen Inc |
"anticuerpos cd20 y su utilización".
|
RU2577125C2
(ru)
|
2010-02-10 |
2016-03-10 |
Фуджифилм Ри Фарма Ко., Лтд. |
Меченное радиоактивным металлом антитело против кадгерина
|
SG183333A1
(en)
|
2010-02-18 |
2012-09-27 |
Genentech Inc |
Neuregulin antagonists and use thereof in treating cancer
|
WO2011101328A2
(en)
|
2010-02-18 |
2011-08-25 |
Roche Glycart Ag |
Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
|
EP2536761B1
(en)
|
2010-02-19 |
2017-09-20 |
The Board Of Regents Of The University Of Oklahoma |
Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
|
JPWO2011105573A1
(ja)
|
2010-02-26 |
2013-06-20 |
株式会社 未来創薬研究所 |
抗icam3抗体およびその用途
|
EP2543727B1
(en)
|
2010-03-02 |
2016-08-31 |
Kyowa Hakko Kirin Co., Ltd. |
Modified antibody composition
|
BR112012022210B1
(pt)
|
2010-03-04 |
2021-08-17 |
Macrogenics, Inc |
Anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
|
GB201003701D0
(en)
|
2010-03-05 |
2010-04-21 |
Cilian Ag |
System for the expression of a protein
|
TW201138823A
(en)
|
2010-03-24 |
2011-11-16 |
Genentech Inc |
Anti-LRP6 antibodies
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
EP3153521B1
(en)
|
2010-03-26 |
2019-09-04 |
Trustees of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
JP5767207B2
(ja)
|
2010-03-26 |
2015-08-19 |
協和発酵キリン株式会社 |
新規修飾部位導入抗体および抗体フラグメント
|
CN102971340A
(zh)
|
2010-03-29 |
2013-03-13 |
酵活有限公司 |
具有增强的或抑制的效应子功能的抗体
|
TWI667257B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
MX360403B
(es)
|
2010-04-15 |
2018-10-31 |
Abbvie Inc |
Proteinas de union a amiloide beta.
|
CA2795544A1
(en)
|
2010-04-27 |
2011-11-03 |
Roche Glycart Ag |
Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
|
WO2011138391A1
(en)
|
2010-05-06 |
2011-11-10 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
CA2798432A1
(en)
|
2010-05-06 |
2011-11-10 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
|
AR081246A1
(es)
|
2010-05-14 |
2012-07-18 |
Abbott Lab |
Proteinas de union a il-1
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
US9169329B2
(en)
|
2010-06-01 |
2015-10-27 |
Ludwig Institute For Cancer Research |
Antibodies directed to the receptor tyrosine kinase c-Met
|
CN103119442A
(zh)
|
2010-06-03 |
2013-05-22 |
霍夫曼-拉罗奇有限公司 |
抗体和免疫偶联物的免疫peg成像及其用途
|
PT2581113T
(pt)
|
2010-06-11 |
2018-07-04 |
Univ Kyushu Nat Univ Corp |
Anticorpo anti-tim-3
|
TW201204388A
(en)
|
2010-06-18 |
2012-02-01 |
Genentech Inc |
Anti-Axl antibodies and methods of use
|
DK3323830T3
(da)
|
2010-06-19 |
2023-09-25 |
Memorial Sloan Kettering Cancer Center |
Anti-gd2 antibodies
|
CA2803391C
(en)
|
2010-06-22 |
2021-11-09 |
Neogenix Oncology, Inc. |
Npc1 antibodies that bind a muc5ac epitope
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
US9534246B2
(en)
|
2010-07-01 |
2017-01-03 |
Glaxo Group Limited |
Method for selecting high producing cell lines
|
EP2592161B1
(en)
|
2010-07-08 |
2016-02-03 |
Honda Motor Co., Ltd. |
High frequency heating coil
|
US20120009196A1
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
RU2571226C2
(ru)
|
2010-07-09 |
2015-12-20 |
Дженентек, Инк. |
Антитела против нейропилина и способы их применения
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
US9120862B2
(en)
|
2010-07-26 |
2015-09-01 |
Abbott Laboratories |
Antibodies relating to PIVKA-II and uses thereof
|
CN105585630B
(zh)
|
2010-07-29 |
2020-09-15 |
Xencor公司 |
具有修改的等电点的抗体
|
EP2598638A2
(en)
|
2010-07-30 |
2013-06-05 |
Glycode |
A yeast artificial chromosome carrying the mammalian glycosylation pathway
|
BR112013002533A2
(pt)
|
2010-08-02 |
2021-09-08 |
Macrogenics, Inc |
Polipeptídeo de ligação de proteína sérica e diacorpo complexado ao polipeptídeo de ligação de proteína sérica
|
RU2013109275A
(ru)
|
2010-08-03 |
2014-09-10 |
Эббви Инк. |
Иммуноглобулины с двумя вариабельными доменами и их применение
|
MX2013001302A
(es)
|
2010-08-03 |
2013-03-08 |
Hoffmann La Roche |
Biomarcadores de leucemia linfocitica (cll).
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
JP2013541937A
(ja)
|
2010-08-05 |
2013-11-21 |
エフ.ホフマン−ラ ロシュ アーゲー |
抗mhc抗体−抗ウイルス性サイトカイン融合タンパク質
|
WO2012020038A1
(en)
|
2010-08-13 |
2012-02-16 |
Roche Glycart Ag |
Anti-tenascin-c a2 antibodies and methods of use
|
NO2603530T3
(da)
|
2010-08-13 |
2018-04-07 |
|
|
WO2012024187A1
(en)
|
2010-08-14 |
2012-02-23 |
Abbott Laboratories |
Amyloid-beta binding proteins
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
TW201208703A
(en)
|
2010-08-17 |
2012-03-01 |
Roche Glycart Ag |
Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
|
NZ604510A
(en)
|
2010-08-17 |
2013-10-25 |
Csl Ltd |
Dilutable biocidal compositions and methods of use
|
PT2606070T
(pt)
|
2010-08-20 |
2017-03-31 |
Novartis Ag |
Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
|
BR112013001847A2
(pt)
|
2010-08-24 |
2016-05-31 |
Hoffmann La Roche |
anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
|
TW201215405A
(en)
|
2010-08-25 |
2012-04-16 |
Hoffmann La Roche |
Antibodies against IL-18R1 and uses thereof
|
KR20130139884A
(ko)
|
2010-08-26 |
2013-12-23 |
애브비 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
US20130224191A1
(en)
|
2010-08-27 |
2013-08-29 |
Robert A. Stull |
Notum protein modulators and methods of use
|
DK2612151T3
(da)
|
2010-08-31 |
2017-10-02 |
Genentech Inc |
Biomarkører og fremgangsmåder til behandling
|
CN106620693A
(zh)
|
2010-09-03 |
2017-05-10 |
艾伯维施特姆森特克斯有限责任公司 |
新型调节剂及使用方法
|
WO2012035518A1
(en)
|
2010-09-17 |
2012-03-22 |
Compugen Ltd. |
Compositions and methods for treatment of drug resistant multiple myeloma
|
WO2012040617A2
(en)
|
2010-09-23 |
2012-03-29 |
Neogenix Oncology, Inc. |
Colon and pancreas cancer peptidomimetics
|
US9228023B2
(en)
|
2010-10-01 |
2016-01-05 |
Oxford Biotherapeutics Ltd. |
Anti-ROR1 antibodies and methods of use for treatment of cancer
|
US8481680B2
(en)
|
2010-10-05 |
2013-07-09 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN103154037A
(zh)
|
2010-10-05 |
2013-06-12 |
诺瓦提斯公司 |
抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
|
AU2011321374B2
(en)
|
2010-10-29 |
2016-04-28 |
Daiichi Sankyo Company,Limited |
Novel anti-DR5 antibody
|
CN103429620B
(zh)
|
2010-11-05 |
2018-03-06 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
PE20140238A1
(es)
|
2010-11-10 |
2014-03-07 |
Genentech Inc |
Metodos y composiciones para inmunoterapia para enfermedad neural
|
JP6013915B2
(ja)
|
2010-11-17 |
2016-10-25 |
中外製薬株式会社 |
血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子
|
BR112013012389A2
(pt)
*
|
2010-11-19 |
2019-09-24 |
Janssen Biotech Inc |
composições de vacina de fragmentos de clivagem de imunoglobina
|
ES2847891T3
(es)
|
2010-11-23 |
2021-08-04 |
Vitaeris Inc |
Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral
|
JP6351973B2
(ja)
|
2010-11-23 |
2018-07-04 |
グラクソ グループ リミテッドGlaxo Group Limited |
抗原結合タンパク質
|
MX2013005847A
(es)
|
2010-11-24 |
2013-12-12 |
Glaxo Group Ltd |
Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
|
CN107973851A
(zh)
|
2010-11-30 |
2018-05-01 |
中外制药株式会社 |
与多分子的抗原重复结合的抗原结合分子
|
KR101026999B1
(ko)
|
2010-12-08 |
2011-04-11 |
재단법인 목암생명공학연구소 |
재조합 단백질의 푸코스 함량을 감소시키는 방법
|
MX356400B
(es)
|
2010-12-08 |
2018-05-28 |
Abbvie Stemcentrx Llc |
Moduladores novedosos y metodos de uso.
|
US9458240B2
(en)
|
2010-12-10 |
2016-10-04 |
Novartis Pharma Ag |
Anti-BAFFR antibody formulations
|
BR112013015122A2
(pt)
|
2010-12-15 |
2017-05-30 |
Wyeth Llc |
anticorpos anti-notch1
|
EP2653541B1
(en)
|
2010-12-15 |
2017-11-08 |
Kyowa Hakko Kirin Co., Ltd. |
Method for producing proteins
|
SG191124A1
(en)
|
2010-12-15 |
2013-07-31 |
Kek High Energy Accelerator |
Protein production method
|
WO2012080389A1
(en)
|
2010-12-16 |
2012-06-21 |
Roche Glycart Ag |
Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
|
TW201732294A
(zh)
|
2010-12-16 |
2017-09-16 |
建南德克公司 |
關於th2抑制作用之診斷及治療
|
BR112013014527A2
(pt)
|
2010-12-20 |
2017-03-07 |
Genentech Inc |
anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina
|
US8853365B2
(en)
|
2010-12-21 |
2014-10-07 |
Abbvie Inc. |
Dual variable domain immunnoglobulins and uses thereof
|
KR20130118925A
(ko)
|
2010-12-22 |
2013-10-30 |
제넨테크, 인크. |
항-pcsk9 항체 및 사용 방법
|
KR101900280B1
(ko)
|
2010-12-23 |
2018-11-08 |
얀센 바이오테크 인코포레이티드 |
활성 프로테아제-저항성 항체 Fc 돌연변이체
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
US9540443B2
(en)
|
2011-01-26 |
2017-01-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies
|
FR2971250A1
(fr)
|
2011-02-07 |
2012-08-10 |
Univ Nantes |
Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese
|
RU2013139267A
(ru)
|
2011-02-10 |
2015-03-20 |
Рош Гликарт Аг |
Улучшенная иммунотерапия
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
CN103403025B
(zh)
|
2011-02-28 |
2016-10-12 |
弗·哈夫曼-拉罗切有限公司 |
单价抗原结合蛋白
|
BR112013019975A2
(pt)
|
2011-02-28 |
2017-08-01 |
Hoffmann La Roche |
proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
|
AU2012222463B9
(en)
|
2011-03-02 |
2017-05-25 |
Roche Glycart Ag |
CEA antibodies
|
EP2895592A1
(en)
|
2011-03-23 |
2015-07-22 |
Société Industrielle Limousine d'Application Biologique (SILAB) |
A yeast recombinant cell capable of producing gdp-fucose
|
EP2691417B1
(en)
|
2011-03-29 |
2018-08-01 |
Roche Glycart AG |
Antibody fc variants
|
JP2014516511A
(ja)
|
2011-04-07 |
2014-07-17 |
ジェネンテック, インコーポレイテッド |
抗fgfr4抗体及び使用方法
|
RU2016147206A
(ru)
|
2011-04-15 |
2018-10-19 |
Компуджен Лтд. |
Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
|
WO2012144208A1
(ja)
|
2011-04-18 |
2012-10-26 |
国立大学法人東京大学 |
抗itm2a抗体を用いる癌の診断および治療
|
CN103703026B
(zh)
|
2011-04-19 |
2015-08-26 |
梅里麦克制药股份有限公司 |
单特异性和双特异性抗igf-1r和抗erbb3抗体
|
TWI561531B
(en)
|
2011-04-25 |
2016-12-11 |
Daiichi Sankyo Co Ltd |
Anti b7-h3 antibody
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
WO2012146630A1
(en)
|
2011-04-29 |
2012-11-01 |
F. Hoffmann-La Roche Ag |
N-terminal acylated polypeptides, methods for their production and uses thereof
|
RU2638806C2
(ru)
|
2011-05-12 |
2017-12-15 |
Дженентек, Инк. |
Lc-ms/ms способ мониторинга множественных реакций для выявления терапевтических антител в образцах животных с помощью каркасных сигнатурных пептидов
|
EP2707391B1
(en)
|
2011-05-13 |
2017-11-08 |
Gamamabs Pharma |
Antibodies against her3
|
RS56090B1
(sr)
|
2011-05-16 |
2017-10-31 |
Hoffmann La Roche |
Fgfr1 agonisti i načini primene
|
UA111612C2
(uk)
|
2011-05-21 |
2016-05-25 |
Макродженікс, Інк. |
Домени, які зв'язуються з деімунізованою сироваткою, і їхнє застосування для збільшення часу напівжиття в сироватці
|
KR102046666B1
(ko)
|
2011-05-25 |
2019-11-19 |
이나뜨 파르마 |
염증성 장애의 치료를 위한 항-kir 항체
|
EA201790330A1
(ru)
|
2011-05-27 |
2018-02-28 |
Глаксо Груп Лимитед |
Белки, связывающиеся с bcma (cd269/tnfrsf17)
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
US9244074B2
(en)
|
2011-06-07 |
2016-01-26 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
RU2650817C2
(ru)
|
2011-06-13 |
2018-04-17 |
Абгеномикс Кооператиф У.А. |
Анти-psgl-1-антитела и их применение
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
AR086924A1
(es)
|
2011-06-15 |
2014-01-29 |
Hoffmann La Roche |
Anticuerpos anti-receptor de epo humano y los metodos para su utilizacion
|
BR112013031762A2
(pt)
|
2011-06-16 |
2016-09-13 |
Novartis Ag |
proteínas solúveis para utilização como terapêuticos
|
KR20140033152A
(ko)
|
2011-06-20 |
2014-03-17 |
교와 핫꼬 기린 가부시키가이샤 |
항erbB3 항체
|
US20140120555A1
(en)
*
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
JP6120833B2
(ja)
|
2011-06-22 |
2017-04-26 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル)Inserm(Institut National Dela Sante Et De La Recherche Medicale) |
抗Axl抗体及びその使用
|
WO2012175691A1
(en)
|
2011-06-22 |
2012-12-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-axl antibodies and uses thereof
|
FR2976811A1
(fr)
|
2011-06-22 |
2012-12-28 |
Lfb Biotechnologies |
Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
|
JP6246711B2
(ja)
|
2011-06-22 |
2017-12-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
複合体を含むmhcクラスiを用いてウイルス特異的細胞傷害性t細胞を循環させることによる標的細胞の除去
|
PT2726094T
(pt)
|
2011-06-28 |
2017-02-10 |
Oxford Biotherapeutics Ltd |
Alvo terapêutico e de diagnóstico
|
PL2726508T3
(pl)
|
2011-06-28 |
2017-12-29 |
Oxford Biotherapeutics Ltd |
Przeciwciała przeciwko cyklazie ADP-rybozylowej 2
|
JP2014522843A
(ja)
|
2011-06-30 |
2014-09-08 |
ジェネンテック, インコーポレイテッド |
抗c−met抗体製剤
|
US9428574B2
(en)
|
2011-06-30 |
2016-08-30 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
HUE040276T2
(hu)
|
2011-07-01 |
2019-02-28 |
Novartis Ag |
Eljárás metabolikus rendellenességek kezelésére
|
UA117901C2
(uk)
|
2011-07-06 |
2018-10-25 |
Ґенмаб Б.В. |
Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
|
RU2640025C2
(ru)
|
2011-07-13 |
2017-12-25 |
Эббви Инк. |
Способы и композиции для лечения астмы с использованием антител против il-13
|
JP2014526886A
(ja)
|
2011-07-15 |
2014-10-09 |
モルフォシス・アー・ゲー |
マクロファージ遊走阻止因子(mif)とd−ドーパクロームトートメラーゼ(d−dt)に交差反応性がある抗体
|
EA028886B1
(ru)
|
2011-07-27 |
2018-01-31 |
Глаксо Груп Лимитед |
ОТДЕЛЬНЫЕ ВАРИАБЕЛЬНЫЕ ДОМЕНЫ ПРОТИВ VEGF, СЛИТЫЕ С Fc-ДОМЕНАМИ
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
WO2013025944A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
EP2744824A1
(en)
|
2011-08-17 |
2014-06-25 |
F.Hoffmann-La Roche Ag |
Neuregulin antibodies and uses thereof
|
KR20140048292A
(ko)
|
2011-08-23 |
2014-04-23 |
로슈 글리카트 아게 |
항-mcsp 항체
|
RU2650775C2
(ru)
|
2011-08-23 |
2018-04-17 |
Рош Гликарт Аг |
Биспецифические антигенсвязывающие молекулы
|
EP2748197A2
(en)
|
2011-08-26 |
2014-07-02 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
BR112014005720A2
(pt)
|
2011-09-15 |
2017-12-12 |
Genentech Inc |
método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método
|
BR112014006419A2
(pt)
|
2011-09-19 |
2018-08-07 |
Genentech Inc |
métodos para tratar um paciente com câncer, kit e artigo
|
MX2014002996A
(es)
|
2011-09-23 |
2014-05-28 |
Roche Glycart Ag |
Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
|
KR102239138B1
(ko)
|
2011-09-30 |
2021-04-12 |
추가이 세이야쿠 가부시키가이샤 |
표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
EA201490644A1
(ru)
|
2011-09-30 |
2014-09-30 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Терапевтические пептиды
|
US20130089562A1
(en)
|
2011-10-05 |
2013-04-11 |
Genenthech, Inc. |
Methods of treating liver conditions using notch2 antagonists
|
AU2012323287B2
(en)
|
2011-10-10 |
2018-02-01 |
Xencor, Inc. |
A method for purifying antibodies
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
EP2766033B1
(en)
|
2011-10-14 |
2019-11-20 |
Novartis AG |
Antibodies and methods for wnt pathway-related diseases
|
US9738727B2
(en)
|
2011-10-14 |
2017-08-22 |
Genentech, Inc. |
Anti-HtrA1 antibodies and methods of use
|
JP6254087B2
(ja)
|
2011-10-15 |
2017-12-27 |
ジェネンテック, インコーポレイテッド |
癌を治療するためのscd1アンタゴニスト
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
WO2013063095A1
(en)
|
2011-10-24 |
2013-05-02 |
Abbvie Inc. |
Immunobinders directed against sclerostin
|
SG11201401815XA
(en)
|
2011-10-28 |
2014-05-29 |
Genentech Inc |
Therapeutic combinations and methods of treating melanoma
|
EP3603671A3
(en)
|
2011-10-28 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Cancer stem cell-specific molecule
|
EP2773664A1
(en)
|
2011-11-01 |
2014-09-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
CA2853951A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Antibodies and methods of treating cancer
|
EP2773373B1
(en)
|
2011-11-01 |
2018-08-22 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
JP6326371B2
(ja)
|
2011-11-04 |
2018-05-16 |
ザイムワークス,インコーポレイテッド |
Fcドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
|
WO2013070565A1
(en)
|
2011-11-07 |
2013-05-16 |
Medimmune, Llc |
Multispecific and multivalent binding proteins and uses thereof
|
AR088920A1
(es)
|
2011-11-21 |
2014-07-16 |
Genentech Inc |
Purificacion de anticuerpos anti-c-met
|
US20130302274A1
(en)
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
SG11201402739YA
(en)
|
2011-12-05 |
2014-06-27 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
|
MX362521B
(es)
|
2011-12-05 |
2019-01-22 |
Novartis Ag |
Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3).
|
WO2013083497A1
(en)
|
2011-12-06 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Antibody formulation
|
WO2013087789A1
(en)
|
2011-12-13 |
2013-06-20 |
Glykos Finland Ltd. |
Antibody isoform arrays and methods thereof
|
SI2794905T1
(sl)
|
2011-12-20 |
2020-08-31 |
Medimmune, Llc |
Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
|
BR112014015111A2
(pt)
|
2011-12-21 |
2017-06-13 |
Novartis Ag |
composições e processos para anticorpos que se direcionam ao fator p
|
PL2794878T3
(pl)
|
2011-12-22 |
2020-07-27 |
F.Hoffmann-La Roche Ag |
Organizacja wektora ekspresyjnego, nowe sposoby generowania komórek produkcyjnych i ich zastosowanie do rekombinowanej produkcji polipeptydów
|
CA3149402A1
(en)
|
2011-12-22 |
2013-06-27 |
F. Hoffman-La Roche Ag |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
CA2854246A1
(en)
|
2011-12-22 |
2013-06-27 |
F. Hoffmann-La Roche Ag |
Full length antibody display system for eukaryotic cells and its use
|
AR089434A1
(es)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
Procedimiento para preparar formulaciones con alta concentracion de proteinas
|
CA3111357A1
(en)
|
2011-12-23 |
2013-06-27 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
TW201333035A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
針對il-13及/或il-17之雙特異性結合蛋白
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
US20140050720A1
(en)
|
2012-01-09 |
2014-02-20 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
WO2013106489A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
JP6242813B2
(ja)
|
2012-01-18 |
2017-12-06 |
ジェネンテック, インコーポレイテッド |
抗lrp5抗体及び使用方法
|
MX2014008699A
(es)
|
2012-01-18 |
2014-11-21 |
Genentech Inc |
Metodos para utilizar moduladores de fgf19.
|
UA118083C2
(uk)
|
2012-01-27 |
2018-11-26 |
Еббві Дойчланд Гмбх Унд Ко. Кг |
ВИДІЛЕНЕ МОНОКЛОНАЛЬНЕ АНТИТІЛО ПРОТИ МОЛЕКУЛИ ВІДШТОВХУВАЛЬНОГО НАПРЯМНОГО СИГНАЛУ (RGMa) ТА ЙОГО ЗАСТОСУВАННЯ В ЛІКУВАННІ РОЗЛАДУ, АСОЦІЙОВАНОГО З ДЕГЕНЕРАЦІЄЮ НЕЙРИТІВ
|
KR20140119777A
(ko)
|
2012-01-31 |
2014-10-10 |
제넨테크, 인크. |
항-ig-e m1'' 항체 및 그의 사용 방법
|
BR112014018481A2
(pt)
|
2012-02-01 |
2017-07-04 |
Compugen Ltd |
anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
|
RU2656183C2
(ru)
|
2012-02-07 |
2018-05-31 |
Иннейт Фарма |
Связывающие mica агенты
|
EP2813568A4
(en)
|
2012-02-09 |
2016-04-06 |
Chugai Pharmaceutical Co Ltd |
MODIFIED FC REGION OF ANTIBODY
|
WO2013119966A2
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
CN113398268A
(zh)
|
2012-02-11 |
2021-09-17 |
霍夫曼-拉罗奇有限公司 |
R-spondin易位及其使用方法
|
CA2860600C
(en)
|
2012-02-15 |
2022-07-26 |
F. Hoffmann-La Roche Ag |
Fc-receptor based affinity chromatography
|
JP6200437B2
(ja)
|
2012-03-16 |
2017-09-20 |
ユニバーシティ ヘルス ネットワーク |
Toso活性を調節するための方法および組成物
|
SG11201406079TA
(en)
|
2012-03-27 |
2014-10-30 |
Genentech Inc |
Diagnosis and treatments relating to her3 inhibitors
|
JP6280031B2
(ja)
|
2012-03-29 |
2018-02-14 |
中外製薬株式会社 |
抗lamp5抗体およびその利用
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
CA2868965A1
(en)
|
2012-03-30 |
2013-10-03 |
Daiichi Sankyo Company, Limited |
Anti-siglec-15 antibody
|
JP6059205B2
(ja)
|
2012-03-30 |
2017-01-11 |
第一三共株式会社 |
CDR改変抗Siglec−15抗体
|
WO2013154206A1
(ja)
|
2012-04-09 |
2013-10-17 |
第一三共株式会社 |
抗fgfr2抗体
|
WO2013155346A1
(en)
|
2012-04-11 |
2013-10-17 |
The Regents Of The University Of California |
Diagnostic tools for response to 6-thiopurine therapy
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
US9334319B2
(en)
|
2012-04-20 |
2016-05-10 |
Abbvie Inc. |
Low acidic species compositions
|
CN104768973B
(zh)
|
2012-04-27 |
2019-01-22 |
第一三共株式会社 |
抗robo4抗体
|
KR20150006000A
(ko)
|
2012-05-01 |
2015-01-15 |
제넨테크, 인크. |
항-pmel17 항체 및 면역접합체
|
EP2847230B1
(en)
|
2012-05-10 |
2020-08-12 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
WO2013174927A1
(en)
|
2012-05-23 |
2013-11-28 |
Novartis International Pharmaceutical Limited |
Production of fucosylated glycoproteins
|
RU2625771C2
(ru)
|
2012-05-23 |
2017-07-18 |
Дженентек, Инк. |
Способ отбора терапевтических средств
|
WO2013174873A1
(en)
|
2012-05-24 |
2013-11-28 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
KR20150016579A
(ko)
|
2012-05-30 |
2015-02-12 |
추가이 세이야쿠 가부시키가이샤 |
표적 조직 특이적 항원 결합 분자
|
EP2855520B1
(en)
|
2012-06-04 |
2018-09-26 |
Novartis AG |
Site-specific labeling methods and molecules produced thereby
|
KR101566539B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Th2 세포 전환용 에피토프 및 이의 용도
|
US9216219B2
(en)
|
2012-06-12 |
2015-12-22 |
Novartis Ag |
Anti-BAFFR antibody formulation
|
WO2013188855A1
(en)
|
2012-06-15 |
2013-12-19 |
Genentech, Inc. |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
AU2013277051B2
(en)
|
2012-06-22 |
2018-06-07 |
King's College London |
Novel VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
BR112014032193A2
(pt)
|
2012-06-27 |
2017-06-27 |
Hoffmann La Roche |
métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico
|
CN104411718B
(zh)
|
2012-06-27 |
2018-04-24 |
弗·哈夫曼-拉罗切有限公司 |
用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
EP3138578B1
(en)
|
2012-07-04 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Anti-theophylline antibodies and methods of use
|
BR112014029403A2
(pt)
|
2012-07-04 |
2018-10-09 |
F. Hoffmann-La Roche Ag |
conjugados, anticorpo e formulação farmacêutica
|
CN104411725B
(zh)
|
2012-07-04 |
2018-09-28 |
弗·哈夫曼-拉罗切有限公司 |
抗生物素抗体及使用方法
|
CA3188124A1
(en)
|
2012-07-05 |
2014-01-09 |
Genentech, Inc. |
Expression and secretion system
|
EP2870973B1
(en)
|
2012-07-06 |
2022-08-31 |
St. Marianna University School of Medicine |
Remedy for htlv-1-associated myelopathy patients
|
EP2869850B1
(en)
|
2012-07-09 |
2017-08-23 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd79b antibodies
|
CA2874856A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd79b antibodies
|
PE20150615A1
(es)
|
2012-07-09 |
2015-05-28 |
Genentech Inc |
Inmunoconjugados que comprenden un anticuerpo anti-cd22 ligado a una pirrolobenzodiazepina
|
MX2015000315A
(es)
|
2012-07-09 |
2015-07-06 |
Genentech Inc |
Anticuerpos anti-cd22 e inmunoconjugados.
|
WO2014011955A2
(en)
|
2012-07-12 |
2014-01-16 |
Abbvie, Inc. |
Il-1 binding proteins
|
EP3495387B1
(en)
|
2012-07-13 |
2021-09-01 |
Roche Glycart AG |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
CN104394887A
(zh)
|
2012-07-18 |
2015-03-04 |
葛莱高托普有限公司 |
采用具有低岩藻糖化的抗her2抗体的新治疗性疗法
|
CN104812775B
(zh)
|
2012-07-25 |
2019-05-03 |
塞尔德克斯医疗公司 |
抗kit抗体及其用途
|
GB201213652D0
(en)
|
2012-08-01 |
2012-09-12 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
ES2700978T3
(es)
|
2012-08-07 |
2019-02-20 |
Roche Glycart Ag |
Composición que comprende dos anticuerpos genomanipulados para que tengan una función efectora reducida e incrementada
|
EP2888279A1
(en)
|
2012-08-22 |
2015-07-01 |
Glaxo Group Limited |
Anti lrp6 antibodies
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
EP3552628A1
(en)
|
2012-09-07 |
2019-10-16 |
The Trustees Of Dartmouth College |
Vista modulators for diagnosis and treatment of cancer
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
CN107501413A
(zh)
|
2012-09-27 |
2017-12-22 |
中外制药株式会社 |
Fgfr3融合基因和以其作为标靶的药物
|
JP6273205B2
(ja)
|
2012-10-05 |
2018-01-31 |
協和発酵キリン株式会社 |
ヘテロダイマータンパク質組成物
|
SI2907824T1
(en)
|
2012-10-11 |
2018-06-29 |
Daiichi Sankyo Company, Limited |
THE HEALTHY KJUBIER OF THE PROTITEL
|
US9872924B2
(en)
|
2012-10-19 |
2018-01-23 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure
|
RU2017137740A
(ru)
|
2012-11-01 |
2019-02-11 |
Эббви Инк. |
Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
|
CN110669136A
(zh)
|
2012-11-05 |
2020-01-10 |
全药工业株式会社 |
抗体或抗体组合物的制备方法
|
AU2013337277B2
(en)
|
2012-11-05 |
2018-03-08 |
Foundation Medicine, Inc. |
Novel NTRK1 fusion molecules and uses thereof
|
CA2884431A1
(en)
|
2012-11-08 |
2014-05-15 |
F. Hoffmann-La Roche Ag |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
EA201590731A1
(ru)
|
2012-11-13 |
2015-11-30 |
Дженентек, Инк. |
Антитела к гемагглютинину и способы применения
|
EP2733153A1
(en)
|
2012-11-15 |
2014-05-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the preparation of immunoconjugates and uses thereof
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
WO2014089113A1
(en)
|
2012-12-03 |
2014-06-12 |
Bristol-Myers Squibb Company |
Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
|
EA033643B1
(ru)
|
2012-12-05 |
2019-11-12 |
Novartis Ag |
Антитело к эритропоэтину или его антигенсвязывающий фрагмент
|
JP6310397B2
(ja)
|
2012-12-06 |
2018-04-11 |
国立大学法人金沢大学 |
中皮腫の治療方法
|
KR20150094617A
(ko)
|
2012-12-07 |
2015-08-19 |
교와 핫꼬 기린 가부시키가이샤 |
항 folr1 항체
|
US20160185847A1
(en)
|
2012-12-17 |
2016-06-30 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Use of monoclonal antibodies for the treatment of inflammation and bacterial infections
|
TWI693073B
(zh)
|
2012-12-21 |
2020-05-11 |
日商中外製藥股份有限公司 |
對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑
|
WO2014100542A1
(en)
|
2012-12-21 |
2014-06-26 |
Abbvie, Inc. |
High-throughput antibody humanization
|
AU2013360775B2
(en)
|
2012-12-21 |
2018-04-12 |
F. Hoffmann-La Roche Ag |
Disulfide-linked multivalent MHC class I comprising multi-function proteins
|
EP4119947A1
(en)
|
2012-12-21 |
2023-01-18 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
|
US9458244B2
(en)
|
2012-12-28 |
2016-10-04 |
Abbvie Inc. |
Single chain multivalent binding protein compositions and methods
|
AU2013370171B2
(en)
|
2012-12-28 |
2018-09-13 |
Precision Biologics, Inc. |
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
|
CN104903352A
(zh)
|
2012-12-28 |
2015-09-09 |
艾伯维公司 |
多价结合蛋白组合物
|
EP2943506B1
(en)
|
2013-01-10 |
2024-03-13 |
Genmab B.V. |
Human igg1 fc region variants and uses thereof
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
WO2014110601A1
(en)
|
2013-01-14 |
2014-07-17 |
Xencor, Inc. |
Novel heterodimeric proteins
|
WO2014113510A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
EP2945652B1
(en)
|
2013-01-18 |
2021-07-07 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
EP2948177A1
(en)
|
2013-01-22 |
2015-12-02 |
AbbVie Inc. |
Methods for optimizing domain stability of binding proteins
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
PL2953972T3
(pl)
|
2013-02-05 |
2021-03-08 |
Engmab Sàrl |
Metoda wyboru przeciwciał przeciwko bcma
|
WO2014124258A2
(en)
|
2013-02-08 |
2014-08-14 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
WO2015198217A2
(en)
|
2013-02-08 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long-acting antibodies targeting il-17
|
EP3929217A3
(en)
|
2013-02-08 |
2022-03-02 |
Novartis AG |
Specific sites for modifying antibodies to make immunoconjugates
|
SI2953969T1
(sl)
|
2013-02-08 |
2020-01-31 |
Novartis Ag |
Protitelesa proti-IL-17A in njihova uporaba v zdravljenju avtoimunskih in vnetnih motenj
|
GB201302447D0
(en)
|
2013-02-12 |
2013-03-27 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
DK3255062T3
(da)
|
2013-02-14 |
2019-10-07 |
Innate Pharma |
Anti-nkp46-antistof til diagnosticering af et ikke-kutant perifert t-cellelymfom (ptcl)
|
CA2899241C
(en)
|
2013-02-20 |
2023-03-28 |
Innate Pharma |
A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma
|
US9328134B2
(en)
|
2013-02-22 |
2016-05-03 |
Amgen Inc. |
Carbohydrate phosphonate derivatives as modulators of glycosylation
|
CA2900097A1
(en)
|
2013-02-22 |
2014-08-28 |
F. Hoffmann-La Roche Ag |
Methods of treating cancer and preventing drug resistance
|
CN104936987A
(zh)
|
2013-02-26 |
2015-09-23 |
罗切格利卡特公司 |
抗mcsp抗体
|
BR112015021462A2
(pt)
|
2013-03-06 |
2017-10-10 |
Adimab Llc |
anticorpos biespecíficos anti-c-met tandem fc
|
US9925240B2
(en)
|
2013-03-06 |
2018-03-27 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
JP6371758B2
(ja)
|
2013-03-12 |
2018-08-08 |
全薬工業株式会社 |
抗ブドウ球菌抗体、その製造方法並びにその使用
|
EP2830651A4
(en)
|
2013-03-12 |
2015-09-02 |
Abbvie Inc |
HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
MX2015012825A
(es)
|
2013-03-14 |
2016-06-10 |
Abbott Lab |
Anticuerpos monoclonales del dominio de union de lipido del núcleo del virus de la hepatitis c vhc.
|
JP2016516046A
(ja)
|
2013-03-14 |
2016-06-02 |
ジェネンテック, インコーポレイテッド |
がんの治療方法及びがん薬物耐性を阻止する方法
|
CN105246916A
(zh)
|
2013-03-14 |
2016-01-13 |
诺华股份有限公司 |
针对notch 3的抗体
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
CN105189552B
(zh)
|
2013-03-14 |
2019-08-02 |
基因泰克公司 |
抗b7-h4抗体和免疫缀合物
|
BR112015023239A8
(pt)
|
2013-03-14 |
2018-04-17 |
Abbott Lab |
ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
|
KR20150127203A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
Mek 억제제 화합물과 her3/egfr 억제제 화합물의 조합물 및 사용 방법
|
CA2906407A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbott Laboratories |
Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
WO2014144763A2
(en)
|
2013-03-15 |
2014-09-18 |
Memorial Sloan Kettering Cancer Center |
High affinity anti-gd2 antibodies
|
US10745483B2
(en)
|
2013-03-15 |
2020-08-18 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
US9550829B2
(en)
|
2013-03-15 |
2017-01-24 |
Genentech, Inc. |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
ES2761260T3
(es)
|
2013-03-15 |
2020-05-19 |
Hoffmann La Roche |
Biomarcadores y procedimientos de tratamiento de afecciones relacionadas con PD-1 y PD-L1
|
DK3587448T3
(da)
|
2013-03-15 |
2021-08-09 |
Xencor Inc |
Heterodimere proteiner
|
ME03796B
(me)
|
2013-03-15 |
2021-04-20 |
Glaxosmithkline Ip Dev Ltd |
Anti-lag-3 vezujući proteini
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
US9260527B2
(en)
|
2013-03-15 |
2016-02-16 |
Sdix, Llc |
Anti-human CXCR4 antibodies and methods of making same
|
BR112015021521A2
(pt)
|
2013-03-15 |
2017-10-10 |
Genentech Inc |
anticorpos anti-crth2 e métodos para seu uso
|
JP6568514B2
(ja)
|
2013-03-15 |
2019-08-28 |
エーシー イミューン エス.エー. |
抗タウ抗体及び使用方法
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US9498543B2
(en)
|
2013-03-15 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
MX2015011899A
(es)
|
2013-03-15 |
2016-05-05 |
Genentech Inc |
Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
|
WO2014145016A2
(en)
|
2013-03-15 |
2014-09-18 |
Genentech, Inc. |
Il-22 polypeptides and il-22 fc fusion proteins and methods of use
|
BR112015023797A2
(pt)
|
2013-03-15 |
2017-10-24 |
Abbvie Inc |
proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
JP2016516800A
(ja)
|
2013-04-22 |
2016-06-09 |
グリコトープ ゲーエムベーハー |
フコシル化が少ない抗egfr抗体による抗がん処置
|
SG10201810481UA
(en)
|
2013-04-29 |
2018-12-28 |
Hoffmann La Roche |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
CA2904806C
(en)
|
2013-04-29 |
2021-11-23 |
F. Hoffmann-La Roche Ag |
Human fcrn-binding modified antibodies and methods of use
|
PL2992010T3
(pl)
|
2013-04-29 |
2021-08-23 |
F.Hoffmann-La Roche Ag |
Modyfikowane asymetryczne przeciwciała wiążące receptor Fc i sposoby ich stosowania
|
EA038367B1
(ru)
|
2013-05-20 |
2021-08-16 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ РЕЦЕПТОРА ТРАНСФЕРРИНА (TfR) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
|
EA201592078A1
(ru)
|
2013-05-31 |
2016-04-29 |
Дженентек, Инк. |
Антитела против тейхоевых кислот клеточной стенки и их конъюгаты
|
EP3004161B1
(en)
|
2013-05-31 |
2019-10-02 |
Genentech, Inc. |
Anti-wall teichoic antibodies and conjugates
|
US9562101B2
(en)
|
2013-06-21 |
2017-02-07 |
Novartis Ag |
Lectin-like oxidized LDL receptor 1 antibodies and methods of use
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
JPWO2014208482A1
(ja)
|
2013-06-24 |
2017-02-23 |
中外製薬株式会社 |
ヒト化抗Epiregulin抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤
|
WO2015010100A2
(en)
|
2013-07-18 |
2015-01-22 |
Fabrus, Inc. |
Humanized antibodies with ultralong complementarity determining regions
|
EP3022224A2
(en)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
SI3027651T1
(sl)
|
2013-08-01 |
2019-05-31 |
Five Prime Therapeutics, Inc. |
Afukozilirana protitelesa proti fgfr2iiib
|
HUE042081T2
(hu)
|
2013-08-09 |
2019-06-28 |
Toray Industries |
Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
|
KR20160042438A
(ko)
|
2013-08-12 |
2016-04-19 |
제넨테크, 인크. |
보체-연관 상태의 치료를 위한 조성물 및 방법
|
KR102337601B1
(ko)
|
2013-08-12 |
2021-12-10 |
아스트라제네카 아베 |
벤랄리주맙을 이용하여 천식 증상을 개선시키는 방법
|
ES2866426T3
(es)
|
2013-08-12 |
2021-10-19 |
Astrazeneca Ab |
Métodos para incrementar el volumen espiratorio forzado en pacientes asmáticos que usan benralizumab
|
LT3033101T
(lt)
|
2013-08-12 |
2019-03-25 |
Astrazeneca Ab |
Astmos paūmejimo dažnio sumažinimo būdai naudojant benralizumabą
|
SG11201600212VA
(en)
|
2013-08-14 |
2016-02-26 |
Novartis Ag |
Methods of treating sporadic inclusion body myositis
|
WO2015033343A1
(en)
|
2013-09-03 |
2015-03-12 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Compositions and methods for expressing recombinant polypeptides
|
KR20160055252A
(ko)
|
2013-09-17 |
2016-05-17 |
제넨테크, 인크. |
항-lgr5 항체의 사용 방법
|
MX2016003643A
(es)
|
2013-09-30 |
2016-12-20 |
Daiichi Sankyo Co Ltd |
Anticuerpo anti-lps o11.
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
CN113667013B
(zh)
|
2013-10-02 |
2024-04-09 |
免疫医疗有限责任公司 |
中和抗甲型流感抗体及其用途
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
EP3056215B1
(en)
|
2013-10-08 |
2019-11-20 |
Daiichi Sankyo Company, Limited |
Combination of anti-fgfr2 antibody and other agent
|
CA2926084A1
(en)
|
2013-10-11 |
2015-04-16 |
Genentech, Inc. |
Nsp4 inhibitors and methods of use
|
EA036927B1
(ru)
|
2013-10-11 |
2021-01-15 |
Оксфорд Биотерепьютикс Лтд |
Конъюгированные антитела против ly75 для лечения рака
|
WO2015054691A2
(en)
|
2013-10-11 |
2015-04-16 |
The United States Of America, As Pepresented By The Secretary, Department Of Health And Human Services |
Tem8 antibodies and their use
|
BR112016006929A2
(pt)
|
2013-10-11 |
2017-09-19 |
Hoffmann La Roche |
Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
|
JP2016534996A
(ja)
*
|
2013-10-15 |
2016-11-10 |
メディミューン,エルエルシー |
ベンラリズマブを使用して慢性閉塞性肺疾患を治療するための方法
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
RU2016114074A
(ru)
|
2013-10-18 |
2017-11-23 |
Дженентек, Инк. |
Анти-rspo антитела и способы применения
|
JP6715767B2
(ja)
|
2013-10-23 |
2020-07-01 |
ジェネンテック, インコーポレイテッド |
好酸球性疾患の診断及び治療方法
|
BR112016010336A2
(pt)
|
2013-11-07 |
2017-10-03 |
Inst Nat Sante Rech Med |
Anticorpo anti-humano-her3 alostérico não competitivo com neuregulina, fragmento de anticorpo, sequência de ácido nucleico, vetor, célula hospedeira, composição farmacêutica e método para tratamento de câncer
|
US20150139988A1
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
KR102399292B1
(ko)
|
2013-11-21 |
2022-05-17 |
에프. 호프만-라 로슈 아게 |
항-알파-시누클레인 항체 및 사용 방법
|
WO2015082446A1
(en)
|
2013-12-02 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-cdcp1 antibody and a taxane
|
AU2014358191B2
(en)
|
2013-12-04 |
2020-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
|
MX371187B
(es)
|
2013-12-06 |
2020-01-22 |
Dana Farber Cancer Inst Inc |
Péptidos terapéuticos.
|
IL298470A
(en)
|
2013-12-09 |
2023-01-01 |
Allakos Inc |
Anti-siglec-8 antibodies and methods of using them
|
SG11201604784XA
(en)
|
2013-12-13 |
2016-07-28 |
Genentech Inc |
Anti-cd33 antibodies and immunoconjugates
|
BR122021025085B1
(pt)
|
2013-12-17 |
2023-04-04 |
Genentech, Inc |
Anticorpo anti-cd3, célula hospedeira procariótica, método de produção do anticorpo biespecífico, imunoconjugado, composição, uso do anticorpo biespecífico e kit
|
JP2017501157A
(ja)
|
2013-12-17 |
2017-01-12 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト及び抗cd20抗体を使用してがんを治療する方法
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
CA2934028A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
KR20240017102A
(ko)
|
2013-12-17 |
2024-02-06 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 이용한 암 치료 방법
|
US10023636B2
(en)
|
2013-12-20 |
2018-07-17 |
Intervet Inc. |
Caninized murine antibodies to human PD-1
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
EP3712174B1
(en)
|
2013-12-24 |
2022-03-16 |
Janssen Pharmaceutica NV |
Anti-vista antibodies and fragments
|
KR102088169B1
(ko)
|
2013-12-25 |
2020-03-12 |
다이이찌 산쿄 가부시키가이샤 |
항 trop2 항체-약물 컨쥬게이트
|
US9758578B2
(en)
|
2013-12-26 |
2017-09-12 |
Mitsubishi Tanabe Pharma Corporation |
Human anti-IL-33 neutralizing monoclonal antibody
|
US10391081B2
(en)
|
2013-12-27 |
2019-08-27 |
Chugai Seiyaku Kabushiki Kaisha |
FGFR gatekeeper mutant gene and drug targeting same
|
WO2015101587A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
RU2682754C2
(ru)
|
2014-01-03 |
2019-03-21 |
Ф. Хоффманн-Ля Рош Аг |
Конъюгаты полипептидного токсина и антитела, соединенных ковалентной связью
|
JP6476194B2
(ja)
|
2014-01-03 |
2019-02-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
二重特異性抗ハプテン/抗血液脳関門受容体抗体、それらの複合体、及び血液脳関門シャトルとしてのそれらの使用
|
EP3092251B1
(en)
|
2014-01-06 |
2021-01-20 |
F. Hoffmann-La Roche AG |
Monovalent blood brain barrier shuttle modules
|
JP6786392B2
(ja)
|
2014-01-15 |
2020-11-18 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
FcRn結合特性が改変され、プロテインA結合特性が保持されているFc領域変異体
|
FR3016633B1
(fr)
|
2014-01-17 |
2018-04-13 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Immunoglobuline anti-toxine du charbon
|
WO2015110923A2
(en)
|
2014-01-21 |
2015-07-30 |
Acerta Pharma B.V. |
Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
|
CN106413756A
(zh)
|
2014-01-24 |
2017-02-15 |
豪夫迈·罗氏有限公司 |
使用抗steap1抗体和免疫缀合物的方法
|
KR102190548B1
(ko)
|
2014-01-31 |
2020-12-14 |
다이이찌 산쿄 가부시키가이샤 |
항-her2 항체-약물 접합체
|
WO2015120075A2
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
KR20210121288A
(ko)
|
2014-02-08 |
2021-10-07 |
제넨테크, 인크. |
알츠하이머 질환을 치료하는 방법
|
SG10201901076WA
(en)
|
2014-02-08 |
2019-03-28 |
Genentech Inc |
Methods of treating alzheimer's disease
|
TWI631135B
(zh)
|
2014-02-12 |
2018-08-01 |
建南德克公司 |
抗jagged1抗體及使用方法
|
CR20160379A
(es)
|
2014-02-21 |
2016-10-07 |
Genentech Inc |
Anticuerpos biespecificos anti-il 13/il-17 y sus usos
|
TWI558399B
(zh)
|
2014-02-26 |
2016-11-21 |
美國禮來大藥廠 |
癌症之組合療法
|
EP4014995A1
(en)
|
2014-02-28 |
2022-06-22 |
Allakos Inc. |
Methods and compositions for treating siglec-8 associated diseases
|
TW201622744A
(zh)
|
2014-03-04 |
2016-07-01 |
美國禮來大藥廠 |
癌症之組合療法
|
US20150252434A1
(en)
|
2014-03-07 |
2015-09-10 |
University Health Network |
Methods and compositions for detection of targets involved in cancer metastasis
|
WO2015138615A2
(en)
|
2014-03-12 |
2015-09-17 |
Irm Llc |
Specific sites for modifying antibodies to make immunoconjugates
|
KR102345173B1
(ko)
|
2014-03-14 |
2021-12-29 |
이나뜨 파르마 에스.에이. |
증가된 안정성을 가진 인간화 항체
|
HRP20211748T1
(hr)
|
2014-03-14 |
2022-02-18 |
F. Hoffmann - La Roche Ag |
Postupci i sastavi za sekreciju heterolognih polipeptida
|
JP2017510631A
(ja)
|
2014-03-14 |
2017-04-13 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
癌に対しnkg2d経路機能を回復させるためのワクチン組成物および方法
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
US20170107294A1
(en)
|
2014-03-21 |
2017-04-20 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
EP3126006A1
(en)
|
2014-03-21 |
2017-02-08 |
AbbVie Inc. |
Anti-egfr antibodies and antibody drug conjugates
|
RU2016141385A
(ru)
|
2014-03-24 |
2018-04-28 |
Дженентек, Инк. |
Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
|
PL3122781T3
(pl)
|
2014-03-28 |
2020-06-15 |
Xencor, Inc. |
Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3
|
PE20161571A1
(es)
|
2014-03-31 |
2017-02-07 |
Genentech Inc |
Anticuerpos anti-ox40 y metodos de uso
|
JP6588461B2
(ja)
|
2014-03-31 |
2019-10-09 |
ジェネンテック, インコーポレイテッド |
抗血管新生剤及びox40結合アゴニストを含む併用療法
|
KR101660580B1
(ko)
|
2014-04-02 |
2016-09-28 |
프레스티지 바이오파마 피티이. 엘티디. |
항체의 당 함량 조절을 통한 항체의 제조 방법
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
KR20240008415A
(ko)
|
2014-04-10 |
2024-01-18 |
다이이찌 산쿄 가부시키가이샤 |
항her3 항체-약물 콘주게이트
|
ES2819863T3
(es)
|
2014-04-11 |
2021-04-19 |
Medimmune Llc |
Anticuerpos contra HER2 biespecíficos
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
EP3141603A4
(en)
|
2014-05-08 |
2017-12-27 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
|
WO2015179658A2
(en)
|
2014-05-22 |
2015-11-26 |
Genentech, Inc. |
Anti-gpc3 antibodies and immunoconjugates
|
CN106661622B
(zh)
|
2014-05-23 |
2020-08-21 |
豪夫迈·罗氏有限公司 |
Mit生物标志物和使用它们的方法
|
ES2761675T3
(es)
|
2014-05-30 |
2020-05-20 |
Henlix Biotech Co Ltd |
Anticuerpos anti-receptor del factor de crecimiento epidérmico (EGFR)
|
ES2894867T3
(es)
|
2014-06-03 |
2022-02-16 |
Xbiotech Inc |
Composiciones y procedimientos de tratamiento y prevención de infecciones por estafilococo áureo
|
EP3998079A1
(en)
|
2014-06-06 |
2022-05-18 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
US11123426B2
(en)
|
2014-06-11 |
2021-09-21 |
The Trustees Of Dartmouth College |
Use of vista agonists and antagonists to suppress or enhance humoral immunity
|
WO2015191715A1
(en)
|
2014-06-11 |
2015-12-17 |
Genentech, Inc. |
Anti-lgr5 antibodies and uses thereof
|
US20230190750A1
(en)
|
2014-06-13 |
2023-06-22 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
MX2016015280A
(es)
|
2014-06-26 |
2017-03-03 |
Hoffmann La Roche |
Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso.
|
WO2015197593A1
(en)
|
2014-06-27 |
2015-12-30 |
Innate Pharma |
MULTISPECIFIC NKp46 BINDING PROTEINS
|
EP3160994A2
(en)
|
2014-06-27 |
2017-05-03 |
Innate Pharma |
Multispecific antigen binding proteins
|
DK3309174T3
(da)
|
2014-07-11 |
2022-06-07 |
Ventana Med Syst Inc |
ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf
|
CA2952315A1
(en)
|
2014-07-11 |
2016-01-14 |
Genentech, Inc. |
Notch pathway inhibition
|
CA2954974A1
(en)
|
2014-07-21 |
2016-01-28 |
Glykos Finland Oy |
Production of glycoproteins with mammalian-like n-glycans in filamentous fungi
|
AU2015292326A1
(en)
|
2014-07-24 |
2017-02-23 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
US10786578B2
(en)
|
2014-08-05 |
2020-09-29 |
Novartis Ag |
CKIT antibody drug conjugates
|
CA2957219A1
(en)
|
2014-08-07 |
2016-02-11 |
Novartis Ag |
Angiopoietin-like 4 antibodies and methods of use
|
EP3194437B1
(en)
|
2014-08-07 |
2021-01-20 |
Novartis AG |
Angiopoietin-like 4 (angptl4) antibodies and methods of use
|
TW201609099A
(zh)
|
2014-08-11 |
2016-03-16 |
艾森塔製藥公司 |
使用布魯頓(Bruton)氏酪胺酸激酶(BTK)抑制劑以治療慢性淋巴球性白血病和小淋巴球性白血病之方法
|
DK3179992T3
(da)
|
2014-08-11 |
2022-07-11 |
Acerta Pharma Bv |
Terapeutisk kombination af en btk-inhibitor, en pd-1-inhibitor og/eller en pd-l1-inhibitor
|
US10238748B2
(en)
|
2014-08-12 |
2019-03-26 |
Novartis Ag |
Anti-CDH6 antibody drug conjugates
|
MD4733C1
(ro)
|
2014-08-19 |
2021-07-31 |
Merck Sharp & Dohme Corp |
Anticorpi anti-TIGIT
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
WO2016030488A1
(en)
|
2014-08-27 |
2016-03-03 |
Innate Pharma |
Treatment of celiac disease
|
ES2913865T3
(es)
|
2014-08-28 |
2022-06-06 |
Bioatla Inc |
Receptores de antígeno quimérico condicionalmente activos para células T modificadas
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
AR101846A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
PL3191135T3
(pl)
|
2014-09-12 |
2021-01-25 |
Genentech, Inc. |
Przeciwciała i immunokoniugaty anty-HER2
|
WO2016040724A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
MX2017003472A
(es)
|
2014-09-17 |
2017-10-31 |
Genentech Inc |
Inmunoconjugados que comprenden anticuerpos anti-her2.
|
SI3262071T1
(sl)
|
2014-09-23 |
2020-07-31 |
F. Hoffmann-La Roche Ag |
Način uporabe imunokonjugatov proti CD79b
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
JP2017531642A
(ja)
|
2014-10-03 |
2017-10-26 |
マサチューセッツ インスティテュート オブ テクノロジー |
エボラ糖タンパク質に結合する抗体およびその使用
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
EP3207057A2
(en)
|
2014-10-16 |
2017-08-23 |
F. Hoffmann-La Roche AG |
Anti-alpha-synuclein antibodies and methods of use
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
US10329348B2
(en)
|
2014-10-23 |
2019-06-25 |
Innate Pharma |
Treatment of cancers using anti-NKG2A agents
|
WO2016070001A1
(en)
|
2014-10-31 |
2016-05-06 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind b7-h4
|
MX2017005751A
(es)
|
2014-11-03 |
2018-04-10 |
Genentech Inc |
Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
|
SG11201703448QA
(en)
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Assays for detecting t cell immune subsets and methods of use thereof
|
CA2961439A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
AR102521A1
(es)
|
2014-11-06 |
2017-03-08 |
Hoffmann La Roche |
Variantes de región fc con unión de fcrn modificada y métodos de utilización
|
CA2963974A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
BR112017006591A2
(pt)
|
2014-11-06 |
2018-01-16 |
Hoffmann La Roche |
polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico
|
CA2960297A1
(en)
|
2014-11-10 |
2016-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
EP3552488A1
(en)
|
2014-11-10 |
2019-10-16 |
F. Hoffmann-La Roche AG |
Animal model for nephropathy and agents for treating the same
|
CA2967188A1
(en)
|
2014-11-14 |
2016-05-19 |
Novartis Ag |
Antibody drug conjugates
|
EP3875481A1
(en)
|
2014-11-14 |
2021-09-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
WO2016081384A1
(en)
|
2014-11-17 |
2016-05-26 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
SI3221359T1
(sl)
|
2014-11-17 |
2020-08-31 |
Regeneron Pharmaceuticals, Inc. |
Metode zravljenja tumorja z uporabo bispecifičnega protitelesa CD3XCD20
|
WO2016081643A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
CN107250158B
(zh)
|
2014-11-19 |
2022-03-25 |
基因泰克公司 |
抗转铁蛋白受体/抗bace1多特异性抗体和使用方法
|
EP3221364B1
(en)
|
2014-11-19 |
2020-12-16 |
Genentech, Inc. |
Antibodies against bace1 and use thereof for neural disease immunotherapy
|
ES2835823T3
(es)
|
2014-11-20 |
2021-06-23 |
Hoffmann La Roche |
Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1
|
SI3221346T1
(sl)
|
2014-11-21 |
2020-11-30 |
Bristol-Myers Squibb Company |
Protitelesa vsebujoča modificirana težko konstantna območja
|
UY36404A
(es)
|
2014-11-21 |
2016-06-01 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN
|
EA037065B1
(ru)
|
2014-11-26 |
2021-02-01 |
Ксенкор, Инк. |
Гетеродимерные антитела, связывающие cd3 и cd38
|
BR112017011092A2
(pt)
|
2014-11-26 |
2017-12-26 |
Xencor Inc |
anticorpos heterodiméricos que ligam cd3 e antígenos de tumor
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
KR20170086536A
(ko)
|
2014-12-03 |
2017-07-26 |
제넨테크, 인크. |
항-스타필로코커스 아우레우스 항체 리파마이신 접합체 및 이의 용도
|
CN107001482B
(zh)
|
2014-12-03 |
2021-06-15 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
RU2017118792A
(ru)
|
2014-12-03 |
2019-01-09 |
Дженентек, Инк. |
Конъюгаты антитела к staphylococcus aureus с рифамицином и их применение
|
EA201790984A1
(ru)
|
2014-12-05 |
2018-05-31 |
Дженентек, Инк. |
Анти-cd79b антитела и способы их применения
|
CN107405398A
(zh)
|
2014-12-05 |
2017-11-28 |
伊穆奈克斯特股份有限公司 |
鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
|
US10398774B2
(en)
|
2014-12-09 |
2019-09-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies against AXL
|
CA2966365A1
(en)
|
2014-12-10 |
2016-06-16 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
WO2016091268A2
(en)
|
2014-12-12 |
2016-06-16 |
University Of Copenhagen |
N-glycosylation
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
CN107278206B
(zh)
|
2014-12-19 |
2021-04-02 |
雷根尼桑斯公司 |
结合人c6的抗体及其用途
|
PL3233921T3
(pl)
|
2014-12-19 |
2022-01-10 |
Chugai Seiyaku Kabushiki Kaisha |
Przeciwciała anty-c5 i sposoby ich stosowania
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
UY36471A
(es)
|
2014-12-23 |
2016-06-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Anticuerpos contra el inmunorreceptor (tigit) de linfocitos t con dominios ig y motivos de inhibición del inmunorreceptor basados en tirosina (itim)
|
WO2016111947A2
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
EP3245231B1
(en)
|
2015-01-16 |
2020-08-12 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for ror1
|
CN113956354A
(zh)
|
2015-01-22 |
2022-01-21 |
中外制药株式会社 |
两种以上抗-c5抗体的组合与使用方法
|
MA41414A
(fr)
|
2015-01-28 |
2017-12-05 |
Centre Nat Rech Scient |
Protéines de liaison agonistes d' icos
|
US10330683B2
(en)
|
2015-02-04 |
2019-06-25 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2016125495A1
(en)
|
2015-02-05 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
EP3256164B1
(en)
|
2015-02-09 |
2020-03-25 |
Memorial Sloan Kettering Cancer Center |
Multi-specific antibodies with affinity for human a33 antigen and dota metal complex
|
WO2016128912A1
(en)
|
2015-02-12 |
2016-08-18 |
Acerta Pharma B.V. |
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
LT3258951T
(lt)
|
2015-02-19 |
2020-05-11 |
Compugen Ltd. |
Anti-pvrig antikūnai ir jų panaudojimo būdai
|
US10550173B2
(en)
|
2015-02-19 |
2020-02-04 |
Compugen, Ltd. |
PVRIG polypeptides and methods of treatment
|
WO2016138160A1
(en)
|
2015-02-24 |
2016-09-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
JP2018511797A
(ja)
|
2015-03-16 |
2018-04-26 |
ジェネンテック, インコーポレイテッド |
IL−13の検出方法及び定量方法並びにTh2関連疾患の診断及び治療における使用
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
RS60270B1
(sr)
|
2015-03-20 |
2020-06-30 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services |
Neutralizacija antitela do gp120 i njihova upotreba
|
EP3072957B1
(en)
|
2015-03-23 |
2019-07-10 |
Lonza Ltd |
Methods for controlling protein glycosylation
|
US10023635B2
(en)
|
2015-03-23 |
2018-07-17 |
Jounce Therapeutics, Inc. |
Antibodies to ICOS
|
EP3590961A1
(en)
|
2015-03-25 |
2020-01-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific multivalent fusion proteins
|
WO2016160976A2
(en)
|
2015-03-30 |
2016-10-06 |
Abbvie Inc. |
Monovalent tnf binding proteins
|
FR3034420A1
(fr)
|
2015-03-31 |
2016-10-07 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-cd303
|
US10858437B2
(en)
|
2015-04-02 |
2020-12-08 |
Intervet, Inc. |
Antibodies to canine interleukin-4 receptor alpha
|
SG11201707490SA
(en)
|
2015-04-03 |
2017-10-30 |
Eureka Therapeutics Inc |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
EP3286315B1
(en)
|
2015-04-24 |
2021-05-26 |
F. Hoffmann-La Roche AG |
Methods of identifying bacteria comprising binding polypeptides
|
AU2016253886B2
(en)
|
2015-04-28 |
2019-05-16 |
Mitsubishi Tanabe Pharma Corporation |
RGMa binding protein and use thereof
|
CN107709363A
(zh)
|
2015-05-01 |
2018-02-16 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
WO2016179517A1
(en)
|
2015-05-07 |
2016-11-10 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
CN107592812A
(zh)
|
2015-05-11 |
2018-01-16 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
CA2983282A1
(en)
|
2015-05-12 |
2016-11-17 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
JP6587696B2
(ja)
*
|
2015-05-13 |
2019-10-09 |
ズムトール バイオロジクス、インコーポレイテッド |
アフコシル化タンパク質、前記タンパク質を発現する細胞、及び関連する方法
|
WO2016188911A1
(en)
|
2015-05-22 |
2016-12-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
|
EP3302563A1
(en)
|
2015-05-29 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Humanized anti-ebola virus glycoprotein antibodies and methods of use
|
AR104809A1
(es)
|
2015-05-29 |
2017-08-16 |
Abbvie Inc |
Anticuerpos anti-cd40 y usos de los mismos
|
CA2984638A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Pd-l1 promoter methylation in cancer
|
JP7144935B2
(ja)
|
2015-05-29 |
2022-09-30 |
ジェネンテック, インコーポレイテッド |
癌のための治療方法及び診断方法
|
BR112017025191A2
(pt)
|
2015-05-29 |
2018-07-31 |
Bristol-Myers Squibb Company |
anticorpos contra ox40 e uso dos mesmos
|
WO2016196679A1
(en)
|
2015-06-02 |
2016-12-08 |
Genentech, Inc. |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
MA44955A
(fr)
|
2015-06-05 |
2019-03-20 |
Ac Immune Sa |
Anticorps anti-tau et leurs méthodes d'utilisation
|
MX2017015690A
(es)
|
2015-06-05 |
2018-07-06 |
Novartis Ag |
Anticuerpos dirigidos a la proteina morfogenetica osea 9 (bmp9) y metodos a partir de estos.
|
CA2988420A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
JP2018521019A
(ja)
|
2015-06-08 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
抗ox40抗体を使用して癌を治療する方法
|
AU2016274767B2
(en)
|
2015-06-09 |
2022-05-19 |
Eureka Therapeutics, Inc. |
T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA
|
US10017577B2
(en)
|
2015-06-15 |
2018-07-10 |
Genentech, Inc. |
Antibodies and immunoconjugates
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
MY189840A
(en)
|
2015-06-16 |
2022-03-11 |
Genentech Inc |
Humanized and affinity matured antibodies to fcrh5 and methods of use
|
EP3310811B1
(en)
|
2015-06-16 |
2021-06-16 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
WO2016205200A1
(en)
|
2015-06-16 |
2016-12-22 |
Genentech, Inc. |
Anti-cll-1 antibodies and methods of use
|
EP3310813A1
(en)
|
2015-06-17 |
2018-04-25 |
Novartis AG |
Antibody drug conjugates
|
MX2017016169A
(es)
|
2015-06-17 |
2018-08-15 |
Genentech Inc |
Anticuerpos anti-her2 y metodos de uso.
|
JP6896650B2
(ja)
|
2015-06-17 |
2021-06-30 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
|
AU2016278239B9
(en)
|
2015-06-17 |
2022-08-11 |
Allakos Inc. |
Methods and compositions for treating fibrotic diseases
|
WO2016207278A1
(en)
|
2015-06-23 |
2016-12-29 |
Innate Pharma |
Multispecific nk engager proteins
|
CN113999312A
(zh)
|
2015-06-24 |
2022-02-01 |
豪夫迈·罗氏有限公司 |
具有定制亲和力的抗转铁蛋白受体抗体
|
CN114805576A
(zh)
|
2015-06-24 |
2022-07-29 |
詹森药业有限公司 |
抗vista抗体和片段
|
EP3108897A1
(en)
|
2015-06-24 |
2016-12-28 |
F. Hoffmann-La Roche AG |
Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
BR112017027690A2
(pt)
|
2015-06-29 |
2018-10-09 |
Daiichi Sankyo Co Ltd |
método para produção de uma composição de conjugado anticorpo-fármaco, e, composição de conjugado anticorpo-fármaco
|
MX2017016645A
(es)
|
2015-06-29 |
2018-11-09 |
Genentech Inc |
Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos.
|
EP3514174B1
(en)
|
2015-06-29 |
2021-03-31 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
FR3038517B1
(fr)
|
2015-07-06 |
2020-02-28 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Utilisation de fragments fc modifies en immunotherapie
|
CA2991980A1
(en)
|
2015-07-13 |
2017-01-19 |
Compugen Ltd. |
Hide1 compositions and methods
|
US10709697B2
(en)
|
2015-07-16 |
2020-07-14 |
Emory University |
Bis-amines, compositions, and uses related to CXCR4 inhibition
|
JP6940479B2
(ja)
|
2015-08-03 |
2021-09-29 |
ノバルティス アーゲー |
Fgf21関連障害を処置する方法
|
EP3331910B1
(en)
|
2015-08-03 |
2019-12-11 |
EngMab Sàrl |
Monoclonal antibodies against human b cell maturation antigen (bcma)
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
US20190008859A1
(en)
|
2015-08-21 |
2019-01-10 |
Acerta Pharma B.V. |
Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
|
CN108026180B
(zh)
|
2015-08-28 |
2022-06-07 |
豪夫迈·罗氏有限公司 |
抗羟腐胺赖氨酸抗体及其用途
|
SG10201913864RA
(en)
|
2015-09-02 |
2020-03-30 |
Immutep Sas |
Anti-LAG-3 Antibodies
|
UY36889A
(es)
|
2015-09-09 |
2017-04-28 |
Novartis Ag |
Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
|
DK3347377T3
(da)
|
2015-09-09 |
2021-05-10 |
Novartis Ag |
Tymisk stromal lymfopoietin (TSLP)-bindende antistoffer og fremgangsmåder til anvendelse af antistofferne
|
US20190022092A1
(en)
|
2015-09-15 |
2019-01-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
|
MA44909A
(fr)
|
2015-09-15 |
2018-07-25 |
Acerta Pharma Bv |
Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
|
US9862760B2
(en)
|
2015-09-16 |
2018-01-09 |
Novartis Ag |
Polyomavirus neutralizing antibodies
|
TWI621628B
(zh)
|
2015-09-18 |
2018-04-21 |
日商中外製藥股份有限公司 |
Il-8結合抗體及其用途
|
EP3353206A1
(en)
|
2015-09-22 |
2018-08-01 |
Spring Bioscience Corporation |
Anti-ox40 antibodies and diagnostic uses thereof
|
KR20180053315A
(ko)
|
2015-09-23 |
2018-05-21 |
제넨테크, 인크. |
항-vegf 항체의 최적화된 변이체들
|
FI3354729T3
(fi)
|
2015-09-24 |
2024-04-23 |
Daiichi Sankyo Co Ltd |
Anti-garp-vasta-aine
|
EP3352791B1
(en)
|
2015-09-24 |
2019-10-30 |
AbVitro LLC |
Hiv antibody compositions and methods of use
|
BR112018005862A2
(pt)
|
2015-09-25 |
2018-10-16 |
Genentech, Inc. |
anticorpos, anticorpos isolados, polinucleotídeo, vetor, célula hospedeira, método de produção do anticorpo, imunoconjugado, composição, usos dos anticorpos, métodos para tratar ou retardar a progressão de um câncer e de uma doença e para aumentar, potencializar ou estimular uma resposta ou função imune e kit
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
PE20181004A1
(es)
|
2015-10-02 |
2018-06-26 |
Hoffmann La Roche |
Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
|
KR20180075537A
(ko)
|
2015-10-06 |
2018-07-04 |
제넨테크, 인크. |
다발성 경화증을 치료하기 위한 방법
|
US10392441B2
(en)
|
2015-10-07 |
2019-08-27 |
United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
KR20180066236A
(ko)
|
2015-10-22 |
2018-06-18 |
조운스 테라퓨틱스, 인크. |
Icos 발현을 계측하기 위한 유전자 특질
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
MA44334A
(fr)
|
2015-10-29 |
2018-09-05 |
Novartis Ag |
Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
|
MX2018005036A
(es)
|
2015-10-29 |
2018-08-01 |
Hoffmann La Roche |
Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
ES2870141T3
(es)
|
2015-10-30 |
2021-10-26 |
Hoffmann La Roche |
Anticuerpos anti-HtrA1 y procedimientos de uso de los mismos
|
CN108289951A
(zh)
|
2015-10-30 |
2018-07-17 |
豪夫迈·罗氏有限公司 |
抗-因子d抗体和缀合物
|
AU2016349392B2
(en)
|
2015-11-03 |
2023-07-13 |
The Trustees Of Columbia University In The City Of New York |
Neutralizing antibodies to HIV-1 gp41 and their use
|
JP6998869B2
(ja)
|
2015-11-08 |
2022-02-04 |
ジェネンテック, インコーポレイテッド |
多重特異性抗体のスクリーニング方法
|
BR112018009972B1
(pt)
|
2015-11-18 |
2021-08-24 |
Merck Sharp & Dohme Corp |
Ligante de ctla4, ligante, recipiente ou dispositivo de injeção, polinucleotídeo, vetor, célula hospedeira, métodos para fabricar o ligante de ctla4 e para prevenir que ctla4 se ligue à cd80 ou cd86 e usos do referido ligante de ctla4
|
EP3377526A1
(en)
|
2015-11-18 |
2018-09-26 |
Merck Sharp & Dohme Corp. |
PD1/CTLA4 Binders
|
TW202216787A
(zh)
|
2015-11-18 |
2022-05-01 |
美商默沙東藥廠 |
Pd1及/或 lag3結合劑
|
WO2017087678A2
(en)
|
2015-11-19 |
2017-05-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
CA3004794A1
(en)
|
2015-11-23 |
2017-06-01 |
Five Prime Therapeutics, Inc. |
Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
|
EP3383903A1
(en)
|
2015-11-30 |
2018-10-10 |
Bristol-Myers Squibb Company |
Anti human ip-10 antibodies and their uses
|
EA201891341A1
(ru)
|
2015-12-04 |
2018-11-30 |
Новартис Аг |
Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции
|
US11623957B2
(en)
|
2015-12-07 |
2023-04-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
MX2018005229A
(es)
|
2015-12-09 |
2019-04-29 |
F HoffmannLa Roche Ag |
Anticuerpo anti-cd20 de tipo ii y usos del mismo.
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
MA43576A
(fr)
|
2015-12-16 |
2018-11-14 |
Merck Sharp & Dohme |
Anticorps anti-lag3 et fragments de fixation à l'antigène
|
WO2017104779A1
(en)
|
2015-12-18 |
2017-06-22 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c5 antibodies and methods of use
|
EP3389711A1
(en)
|
2015-12-18 |
2018-10-24 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
CA3006529A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
WO2017122175A1
(en)
|
2016-01-13 |
2017-07-20 |
Acerta Pharma B.V. |
Therapeutic combinations of an antifolate and a btk inhibitor
|
CN108602883A
(zh)
|
2016-01-20 |
2018-09-28 |
基因泰克公司 |
用于阿尔茨海默氏病的高剂量治疗
|
CN109071625A
(zh)
|
2016-02-04 |
2018-12-21 |
柯瑞斯公司 |
平滑化突变体和其使用方法
|
WO2017136820A2
(en)
|
2016-02-06 |
2017-08-10 |
Epimab Biotherapeutics, Inc. |
Fabs-in-tandem immunoglobulin and uses thereof
|
WO2017137830A1
(en)
|
2016-02-12 |
2017-08-17 |
Janssen Pharmaceutica Nv |
Anti-vista (b7h5) antibodies
|
JP2019511911A
(ja)
|
2016-02-17 |
2019-05-09 |
ノバルティス アーゲー |
Tgfベータ2抗体
|
MX2018010361A
(es)
|
2016-02-29 |
2019-07-08 |
Genentech Inc |
Métodos terapéuticos y de diagnóstico para el cáncer.
|
WO2017148879A1
(en)
|
2016-03-01 |
2017-09-08 |
F. Hoffmann-La Roche Ag |
Obinutuzumab and rituximab variants having reduced adcp
|
CA3016187A1
(en)
|
2016-03-04 |
2017-09-08 |
Bristol-Myers Squibb Company |
Combination therapy with anti-cd73 antibodies
|
WO2017157895A1
(en)
|
2016-03-15 |
2017-09-21 |
Innate Pharma |
Anti-mica antibodies
|
AU2017235097B2
(en)
|
2016-03-15 |
2023-08-31 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
|
CN109641955B
(zh)
|
2016-03-22 |
2022-07-08 |
国家医疗保健研究所 |
人源化抗claudin-1抗体及其用途
|
WO2017161414A1
(en)
|
2016-03-22 |
2017-09-28 |
Bionomics Limited |
Administration of an anti-lgr5 monoclonal antibody
|
WO2017165734A1
(en)
|
2016-03-25 |
2017-09-28 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
US11104739B2
(en)
|
2016-04-14 |
2021-08-31 |
Bristol-Myers Squibb Company |
Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody
|
EP3865511A1
(en)
|
2016-04-14 |
2021-08-18 |
F. Hoffmann-La Roche AG |
Anti-rspo3 antibodies and methods of use
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
SG11201808994YA
(en)
|
2016-04-15 |
2018-11-29 |
Bioatla Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
AU2017250294B2
(en)
|
2016-04-15 |
2022-07-21 |
Immunext Inc. |
Anti-human VISTA antibodies and use thereof
|
EP3445393A4
(en)
|
2016-04-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
CMV NEUTRALIZATION ANTIGEN BINDING PROTEINS
|
US11312766B2
(en)
|
2016-04-27 |
2022-04-26 |
Novartis Ag |
Antibodies against growth differentiation factor 15 and uses thereof
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
BR112018069890A2
(pt)
|
2016-05-02 |
2019-02-05 |
Hoffmann La Roche |
polipeptídio de fusão que se liga de forma específica a um alvo, polipeptídio de fusão dimérico, ácido nucleico isolado, par de ácidos nucleicos isolados, célula hospedeira, método para produzir um polipeptídio de fusão, imunoconjugado, formulação farmacêutica, polipeptídio de fusão e uso do polipeptídio de fusão
|
WO2017194441A1
(en)
|
2016-05-11 |
2017-11-16 |
F. Hoffmann-La Roche Ag |
Modified anti-tenascin antibodies and methods of use
|
SI3455261T1
(sl)
|
2016-05-13 |
2023-01-31 |
Bioatla, Inc. |
Protitelesa proti ROR2, fragmenti protitelesa, njihovi imunokonjugati in uporabe le-teh
|
KR20230021765A
(ko)
|
2016-05-18 |
2023-02-14 |
젠맵 비. 브이 |
항체 및 감염성 질환의 치료에서의 그의 사용 방법
|
ES2858151T3
(es)
|
2016-05-20 |
2021-09-29 |
Hoffmann La Roche |
Conjugados de PROTAC-anticuerpo y procedimientos de uso
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
EP3465221B1
(en)
|
2016-05-27 |
2020-07-22 |
H. Hoffnabb-La Roche Ag |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
US20200002432A1
(en)
|
2016-06-08 |
2020-01-02 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
EP3468993A1
(en)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
RU2018147224A
(ru)
|
2016-06-08 |
2020-07-14 |
Эббви Инк. |
Конъюгаты антитела к egfr и лекарственного средства
|
CA3027173A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-egfr antibody drug conjugates
|
BR112018075649A2
(pt)
|
2016-06-08 |
2019-04-09 |
Abbvie Inc. |
anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
|
CN116284404A
(zh)
|
2016-06-08 |
2023-06-23 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
JP2019524649A
(ja)
|
2016-06-08 |
2019-09-05 |
アッヴィ・インコーポレイテッド |
抗cd98抗体及び抗体薬物コンジュゲート
|
JP2019522643A
(ja)
|
2016-06-08 |
2019-08-15 |
アッヴィ・インコーポレイテッド |
抗cd98抗体及び抗体薬物コンジュゲート
|
CA3026880A1
(en)
|
2016-06-08 |
2017-12-14 |
Paul Foster |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
CN109562190A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗egfr抗体药物偶联物
|
KR20230054508A
(ko)
|
2016-06-14 |
2023-04-24 |
젠코어 인코포레이티드 |
이중특이적 체크포인트 억제제 항체
|
US11434269B2
(en)
|
2016-06-15 |
2022-09-06 |
Novartis Ag |
Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
|
EP3257866A1
(en)
|
2016-06-17 |
2017-12-20 |
Academisch Medisch Centrum |
Modified anti-tnf antibody and use thereof in the treatment of ibd
|
EP3475298A1
(en)
|
2016-06-24 |
2019-05-01 |
H. Hoffnabb-La Roche Ag |
Anti-polyubiquitin multispecific antibodies
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
BR112019000431A2
(pt)
|
2016-07-14 |
2019-07-09 |
Bristol-Myers Squibb Company |
anticorpos contra tim3 e usos dos mesmos
|
WO2018013917A1
(en)
|
2016-07-15 |
2018-01-18 |
Takeda Pharmaceutical Company Limited |
Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
WO2018021450A1
(ja)
|
2016-07-29 |
2018-02-01 |
中外製薬株式会社 |
増強されたfviii補因子機能代替活性を有する二重特異性抗体
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
JP2019525934A
(ja)
|
2016-07-29 |
2019-09-12 |
イーライ リリー アンド カンパニー |
癌の治療に使用するためのメレスチニブおよび抗pd−l1または抗pd−1阻害剤を用いた組み合わせ治療
|
KR102553195B1
(ko)
|
2016-07-29 |
2023-07-07 |
주노 쎄러퓨티크스 인코퍼레이티드 |
항-cd19 항체에 대한 항-이디오타입 항체
|
CN109661406A
(zh)
|
2016-07-29 |
2019-04-19 |
国家医疗保健研究所 |
靶向肿瘤相关巨噬细胞的抗体及其用途
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
EP3494141A4
(en)
|
2016-08-03 |
2020-04-08 |
Bio-Techne Corporation |
IDENTIFICATION OF VSIG3 / VISTA AS A NEW IMMUNE CONTROL POINT AND ITS USE IN IMMUNOTHERAPY
|
RU2766112C2
(ru)
|
2016-08-05 |
2022-02-08 |
Чугаи Сейяку Кабусики Кайся |
Композиция для профилактики или лечения связанных с il-8 заболеваний
|
KR20190035863A
(ko)
|
2016-08-05 |
2019-04-03 |
알라코스 인크. |
암 치료를 위한 항Siglec-7 항체
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
JP7033328B2
(ja)
|
2016-08-16 |
2022-03-10 |
エピムアブ バイオセラピューティクス インコーポレイテッド |
一価の非対称タンデムFab二重特異性抗体
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
US10981976B2
(en)
|
2016-08-31 |
2021-04-20 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
|
CA3035081A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
EP3510046A4
(en)
|
2016-09-07 |
2020-05-06 |
The Regents of the University of California |
ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES
|
US20190270821A1
(en)
|
2016-09-13 |
2019-09-05 |
Humanigen, Inc. |
Epha3 antibodies for the treatment of pulmonary fibrosis
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
CN109689682B
(zh)
|
2016-09-19 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
基于补体因子的亲和层析
|
TWI787203B
(zh)
|
2016-09-23 |
2022-12-21 |
美商建南德克公司 |
Il-13拮抗劑用於治療異位性皮炎之用途
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
EP3519433A1
(en)
|
2016-10-03 |
2019-08-07 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
CN110139674B
(zh)
|
2016-10-05 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
制备抗体药物缀合物的方法
|
KR20190072528A
(ko)
|
2016-10-06 |
2019-06-25 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
CN109789211A
(zh)
|
2016-10-07 |
2019-05-21 |
第一三共株式会社 |
基于抗her2抗体-药物偶联物施予的耐性癌的治疗
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
CU20200105A7
(es)
|
2016-10-13 |
2021-08-06 |
Massachusetts Inst Technology |
Anticuerpos que se unen a la proteína de envoltura del virus zika
|
CN110214147A
(zh)
|
2016-10-14 |
2019-09-06 |
Xencor股份有限公司 |
IL15/IL15Rα异源二聚体FC-融合蛋白
|
KR20190068602A
(ko)
|
2016-10-21 |
2019-06-18 |
이나뜨 파르마 |
항-kir3dl2 작용제에 의한 치료
|
AU2017351764A1
(en)
|
2016-10-25 |
2019-06-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Monoclonal antibodies binding to the CD160 transmembrane isoform
|
JP7206590B2
(ja)
|
2016-10-28 |
2023-01-18 |
東レ株式会社 |
癌の治療及び/又は予防用医薬組成物
|
CN110352073A
(zh)
|
2016-10-28 |
2019-10-18 |
机敏医药股份有限公司 |
针对timp-2的抗体用于改善肾功能的用途
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック, インコーポレイテッド |
抗mic抗体及び使用方法
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
BR112019008702A2
(pt)
|
2016-11-01 |
2019-07-16 |
Genmab B.V. |
polipeptídeo, método de diminuição de uma função fc efetora de um polipeptídeo, composição, método de tratamento, kit de partes, e, uso de um polipeptídeo ou composição.
|
LT3535298T
(lt)
|
2016-11-02 |
2021-12-27 |
Jounce Therapeutics, Inc. |
Antikūnai prieš pd-1 ir jų panaudojimas
|
AU2017353427A1
(en)
|
2016-11-02 |
2019-05-16 |
Bristol-Myers Squibb Company |
Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
|
CN110072890B
(zh)
|
2016-11-03 |
2022-11-29 |
百时美施贵宝公司 |
可活化的抗ctla-4抗体及其用途
|
CN109996809A
(zh)
|
2016-11-14 |
2019-07-09 |
诺华股份有限公司 |
与促融合蛋白minion相关的组合物、方法和治疗用途
|
MX2019005438A
(es)
|
2016-11-15 |
2019-08-16 |
Genentech Inc |
Dosificacion para tratamiento con anticuerpos bispecificos anti-cd20 / anti-cd3.
|
CN109963562A
(zh)
|
2016-11-16 |
2019-07-02 |
伊莱利利公司 |
用于具有外显子14跳读突变或外显子14跳读表型的癌症的组合疗法
|
EP3468991A1
(en)
|
2016-11-21 |
2019-04-17 |
cureab GmbH |
Anti-gp73 antibodies and immunoconjugates
|
JP7227146B2
(ja)
|
2016-11-23 |
2023-02-21 |
バイオベラティブ セラピューティクス インコーポレイテッド |
凝固第ix因子および凝固第x因子に結合する二重特異性抗体
|
EP3544628A4
(en)
|
2016-11-23 |
2020-11-18 |
Immunoah Therapeutics, Inc. |
4-1BB BINDING PROTEINS AND THEIR USES
|
WO2018101448A1
(en)
|
2016-11-30 |
2018-06-07 |
Kyowa Hakko Kirin Co., Ltd. |
Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody
|
WO2018102746A1
(en)
|
2016-12-02 |
2018-06-07 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to tigit
|
PE20190921A1
(es)
|
2016-12-07 |
2019-06-26 |
Agenus Inc |
Anticuerpos y metodos de su utilizacion
|
CA3045294A1
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc. |
Anti-tau antibodies and methods of use
|
MX2019006334A
(es)
|
2016-12-07 |
2019-08-01 |
Genentech Inc |
Anticuerpos antitau y métodos de uso.
|
EP3551663A1
(en)
|
2016-12-12 |
2019-10-16 |
H. Hoffnabb-La Roche Ag |
Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
|
EP3552626A4
(en)
|
2016-12-12 |
2020-06-10 |
Daiichi Sankyo Company, Limited |
ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR
|
JP7202185B2
(ja)
|
2016-12-22 |
2023-01-11 |
第一三共株式会社 |
抗cd3抗体及び該抗体を含む分子
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
US20190322767A1
(en)
|
2016-12-23 |
2019-10-24 |
Innate Pharma |
Heterodimeric antigen binding proteins
|
AU2017383232A1
(en)
|
2016-12-23 |
2019-06-27 |
Novartis Ag |
Factor XI antibodies and methods of use
|
US20180230218A1
(en)
|
2017-01-04 |
2018-08-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
CA3049163A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
WO2018129336A1
(en)
|
2017-01-06 |
2018-07-12 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
US10174122B2
(en)
|
2017-01-06 |
2019-01-08 |
Eutilex Co., Ltd. |
Anti-human 4-1BB antibodies and uses thereof
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
CA3049435A1
(en)
|
2017-01-09 |
2018-07-12 |
Scott Grindrod |
Selective histone deacetylase inhibitors for the treatment of human disease
|
WO2018132597A1
(en)
|
2017-01-12 |
2018-07-19 |
Eureka Therapeutics, Inc. |
Constructs targeting histone h3 peptide/mhc complexes and uses thereof
|
CN110382535A
(zh)
|
2017-01-17 |
2019-10-25 |
第一三共株式会社 |
抗-gpr20抗体以及抗-gpr20抗体-药物缀合物
|
US11208491B2
(en)
|
2017-01-24 |
2021-12-28 |
Kyowa Kirin Co., Ltd. |
Treatment or prevention method of radiation damage by administration of IL-5 receptor alpha chain binding antibody
|
KR20190133160A
(ko)
|
2017-02-07 |
2019-12-02 |
다이이찌 산쿄 가부시키가이샤 |
항-gprc5d 항체 및 항-gprc5d 항체를 포함하는 분자
|
BR112019016344A2
(pt)
|
2017-02-08 |
2020-04-07 |
Novartis Ag |
anticorpos miméticos fgf21 e usos dos mesmos
|
US11471538B2
(en)
|
2017-02-10 |
2022-10-18 |
INSERM (Institut National de la Santéet de la Recherche Medicale) |
Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the MAPK pathway
|
AU2018217816A1
(en)
|
2017-02-10 |
2019-08-15 |
Genentech, Inc. |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
SG11201907242TA
(en)
|
2017-02-10 |
2019-09-27 |
Eutilex Co Ltd |
IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF
|
US11021535B2
(en)
|
2017-02-10 |
2021-06-01 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
CA3053222A1
(en)
|
2017-02-10 |
2018-08-16 |
Genmab B.V. |
Polypeptide variants and uses thereof
|
BR112019016374A2
(pt)
|
2017-02-17 |
2020-04-07 |
Bristol-Myers Squibb Company |
anticorpos para alfa-sinucleína e usos dos mesmos
|
KR20190120764A
(ko)
|
2017-02-28 |
2019-10-24 |
갓코 호진 긴키 다이가쿠 |
항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법
|
BR112019017695A2
(pt)
|
2017-02-28 |
2020-04-07 |
Bristol-Myers Squibb Company |
uso de anticorpos anti-ctla-4 com adcc acentuada para acentuar a resposta imune a uma vacina
|
WO2018160841A1
(en)
|
2017-03-01 |
2018-09-07 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
CA3054778A1
(en)
|
2017-03-02 |
2018-09-07 |
Kyowa Kirin Co., Ltd. |
Preventive or therapeutic agent for htlv-1 associated myelopathy using low-dose of anti-ccr4 antibody
|
JP2020510432A
(ja)
|
2017-03-02 |
2020-04-09 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Nectin−4への特異性を有する抗体及びその使用
|
KR20190138636A
(ko)
|
2017-03-22 |
2019-12-13 |
제넨테크, 인크. |
안구 장애의 치료를 위한 최적화된 항체 조성물
|
US10982000B2
(en)
|
2017-03-24 |
2021-04-20 |
Novartis Ag |
Methods for treating and/or reducing the likelihood of heart failure by administering anti-activin receptor type II (anti-ActRII) antibody
|
CN110494446A
(zh)
|
2017-03-28 |
2019-11-22 |
基因泰克公司 |
治疗神经退行性疾病的方法
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
TWI796329B
(zh)
|
2017-04-07 |
2023-03-21 |
美商默沙東有限責任公司 |
抗-ilt4抗體及抗原結合片段
|
SG11201908813QA
(en)
|
2017-04-13 |
2019-10-30 |
Aduro Biotech Holdings Europe B V |
Anti-sirp alpha antibodies
|
JP2020516253A
(ja)
|
2017-04-14 |
2020-06-11 |
ジェネンテック, インコーポレイテッド |
がんのための診断及び治療方法
|
EP3612567A4
(en)
|
2017-04-19 |
2020-11-11 |
Bluefin Biomedicine, Inc. |
ANTI-VTCN1 ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
|
MA49131A
(fr)
|
2017-04-21 |
2020-03-25 |
Hoffmann La Roche |
Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
|
WO2018200586A1
(en)
|
2017-04-26 |
2018-11-01 |
Eureka Therapeutics, Inc. |
Constructs specifically recognizing glypican 3 and uses thereof
|
SG10201913677SA
(en)
|
2017-04-27 |
2020-03-30 |
Tesaro Inc |
Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
AU2018261887A1
(en)
|
2017-05-05 |
2019-12-05 |
Allakos Inc. |
Methods and compositions for treating allergic ocular diseases
|
WO2018209125A1
(en)
|
2017-05-10 |
2018-11-15 |
Fred Hutchinson Cancer Research Center |
Epstein barr virus antibodies, vaccines, and uses of the same
|
WO2018209115A1
(en)
|
2017-05-10 |
2018-11-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
CN111094335B
(zh)
|
2017-05-15 |
2022-08-23 |
罗切斯特大学 |
广泛中和的抗流感单克隆抗体及其用途
|
TWI794230B
(zh)
|
2017-05-15 |
2023-03-01 |
日商第一三共股份有限公司 |
抗cdh6抗體及抗cdh6抗體-藥物結合物、以及其製造方法
|
US11091555B2
(en)
|
2017-05-16 |
2021-08-17 |
Five Prime Therapeutics, Inc. |
Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy
|
WO2018215938A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
JP2020520665A
(ja)
|
2017-05-24 |
2020-07-16 |
ノバルティス アーゲー |
抗体−サイトカイングラフト化タンパク質及び癌の治療における使用方法
|
EP4098662A1
(en)
|
2017-05-25 |
2022-12-07 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
BR112019025352A8
(pt)
|
2017-05-29 |
2023-05-02 |
Inst Nat Sante Rech Med |
Inibidor de imunossupressão associada ao câncer
|
SG10202111336RA
(en)
|
2017-06-01 |
2021-11-29 |
Compugen Ltd |
Triple combination antibody therapies
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
WO2018229706A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
JP2020529832A
(ja)
|
2017-06-30 |
2020-10-15 |
ゼンコア インコーポレイテッド |
IL−15/IL−15Rαおよび抗原結合ドメインを含む標的化ヘテロダイマーFc融合タンパク質
|
GB201710973D0
(en)
|
2017-07-07 |
2017-08-23 |
Avacta Life Sciences Ltd |
Scaffold proteins
|
CA3069438A1
(en)
|
2017-07-11 |
2019-01-17 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
KR20200029469A
(ko)
|
2017-07-18 |
2020-03-18 |
쿄와 기린 가부시키가이샤 |
항인간 ccr1 모노클로날 항체
|
TWI823859B
(zh)
|
2017-07-21 |
2023-12-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
SG11202000658PA
(en)
|
2017-07-26 |
2020-02-27 |
Forty Seven Inc |
Anti-sirp-alpha antibodies and related methods
|
EP3660155A4
(en)
|
2017-07-27 |
2021-04-07 |
Daiichi Sankyo Company, Limited |
ANTI-CD147 ANTIBODY
|
MA49987A
(fr)
|
2017-08-23 |
2020-07-01 |
Daiichi Sankyo Co Ltd |
Préparation de conjugué anticorps-médicament et lyophilisation associée
|
SG11202000387YA
(en)
|
2017-08-25 |
2020-03-30 |
Five Prime Therapeutics Inc |
B7-h4 antibodies and methods of use thereof
|
CN111065621B
(zh)
|
2017-08-31 |
2024-01-26 |
第一三共株式会社 |
制备抗体-药物缀合物的新方法
|
SG11202000997YA
(en)
|
2017-08-31 |
2020-03-30 |
Daiichi Sankyo Co Ltd |
Improved method for producing antibody-drug conjugate
|
EP3684413A1
(en)
|
2017-09-20 |
2020-07-29 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
IL301638B1
(en)
|
2017-09-29 |
2024-05-01 |
Daiichi Sankyo Co Ltd |
Conjugation of an antibody with a pyrrolobenzodiazepine derivative
|
EP4215543A3
(en)
|
2017-10-03 |
2023-10-11 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
CA3078436A1
(en)
|
2017-10-05 |
2019-04-11 |
Daiichi Sankyo Company, Limited |
Composition for cytotoxic t cell depletion
|
US11230601B2
(en)
|
2017-10-10 |
2022-01-25 |
Tilos Therapeutics, Inc. |
Methods of using anti-lap antibodies
|
CA3185107A1
(en)
|
2017-10-12 |
2019-04-18 |
Immunowake Inc. |
Vegfr-antibody light chain fusion protein
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
JP7256197B2
(ja)
|
2017-11-01 |
2023-04-11 |
ジュノー セラピューティクス インコーポレイテッド |
B細胞成熟抗原に特異的な抗体およびキメラ抗原受容体
|
TW201923089A
(zh)
|
2017-11-06 |
2019-06-16 |
美商建南德克公司 |
癌症之診斷及治療方法
|
JP2021502100A
(ja)
|
2017-11-08 |
2021-01-28 |
ゼンコア インコーポレイテッド |
新規抗pd−1配列を用いた二重特異性および単一特異性抗体
|
US11773180B2
(en)
|
2017-11-08 |
2023-10-03 |
Kyowa Kirin Co., Ltd. |
Bispecific antibody which binds to CD40 and EpCAM
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2019100052A2
(en)
|
2017-11-20 |
2019-05-23 |
Compass Therapeutics Llc |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
AU2018371114A1
(en)
|
2017-11-21 |
2020-05-07 |
Innate Pharma |
Multispecific antigen binding proteins
|
JP2021503885A
(ja)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
末梢血からの末梢血リンパ球(pbl)の拡大培養
|
CN111902427A
(zh)
|
2017-11-22 |
2020-11-06 |
诺华股份有限公司 |
抗因子XI/XIa抗体的逆转结合剂及其用途
|
AU2018375331A1
(en)
|
2017-12-01 |
2020-05-14 |
Pfizer Inc. |
Anti-CXCR5 antibodies and compositions and uses thereof
|
JP2021508439A
(ja)
|
2017-12-01 |
2021-03-11 |
ノバルティス アーゲー |
ポリオーマウイルス中和抗体
|
WO2019106193A1
(en)
|
2017-12-01 |
2019-06-06 |
University Of Copenhagen |
Peptide hormone with one or more o-glycans
|
EP3498293A1
(en)
|
2017-12-15 |
2019-06-19 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Treatment of monogenic diseases with an anti-cd45rc antibody
|
JP2021508104A
(ja)
|
2017-12-15 |
2021-02-25 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
|
MA51184A
(fr)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics Inc |
Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
|
US11319355B2
(en)
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
EP3728321A1
(en)
|
2017-12-22 |
2020-10-28 |
F. Hoffmann-La Roche AG |
Use of pilra binding agents for treatment of a disease
|
EA202091540A1
(ru)
|
2017-12-22 |
2021-03-22 |
Джаунс Терапьютикс, Инк. |
Антитела к lilrb2
|
CN109970857B
(zh)
|
2017-12-27 |
2022-09-30 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
WO2019129136A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
WO2019129137A1
(zh)
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
CN112041341B
(zh)
|
2017-12-28 |
2024-05-24 |
机敏医药股份有限公司 |
Ccl14的抗体和检测
|
AU2018396970A1
(en)
|
2017-12-28 |
2020-08-13 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against TIGIT
|
EP3732203A4
(en)
|
2017-12-28 |
2021-12-15 |
Nanjing Legend Biotech Co., Ltd. |
ANTIBODIES AND VARIANTS THEREOF AGAINST PD-L1
|
EP3724223A1
(en)
|
2018-01-02 |
2020-10-21 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
KR20200106525A
(ko)
|
2018-01-05 |
2020-09-14 |
에이씨 이뮨 에스.에이. |
미스폴딩된 tdp-43 결합 분자
|
CA3087565A1
(en)
|
2018-01-09 |
2019-07-18 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
JP7358361B2
(ja)
|
2018-01-12 |
2023-10-10 |
ブリストル-マイヤーズ スクイブ カンパニー |
Tim3に対する抗体およびその使用
|
US11713353B2
(en)
|
2018-01-15 |
2023-08-01 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against PD-1
|
EP3740505A1
(en)
|
2018-01-16 |
2020-11-25 |
Lakepharma Inc. |
Bispecific antibody that binds cd3 and another target
|
JP7349995B2
(ja)
|
2018-01-26 |
2023-09-25 |
ジェネンテック, インコーポレイテッド |
IL-22 Fc融合タンパク質及び使用方法
|
RS63812B1
(sr)
|
2018-01-26 |
2023-01-31 |
Hoffmann La Roche |
Il-22 fc kompozicije i postupci primene
|
JP7438953B2
(ja)
|
2018-02-01 |
2024-02-27 |
イノベント バイオロジックス (スウツォウ) カンパニー,リミテッド |
完全ヒト化抗b細胞成熟抗原(bcma)の単鎖抗体およびその応用
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
EP3746477A1
(en)
|
2018-02-02 |
2020-12-09 |
Bio-Techne Corporation |
Compounds that modulate the interaction of vista and vsig3 and methods of making and using
|
US11866498B2
(en)
|
2018-02-08 |
2024-01-09 |
Genentech, Inc. |
Bispecific antigen-binding molecules and methods of use
|
MX2020008291A
(es)
|
2018-02-09 |
2020-09-25 |
Genentech Inc |
Metodos terapeuticos y diagnosticos para enfermedades inflamatorias mediadas por mastocitos.
|
JP2021512962A
(ja)
|
2018-02-13 |
2021-05-20 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
アデノシンa2a受容体アンタゴニストによる腫瘍浸潤性リンパ球(til)の拡大培養並びにtil及びアデノシンa2a受容体アンタゴニストの治療的組み合わせ
|
EP3752530A1
(en)
|
2018-02-14 |
2020-12-23 |
ABBA Therapeutics AG |
Anti-human pd-l2 antibodies
|
WO2019165077A1
(en)
|
2018-02-21 |
2019-08-29 |
Five Prime Therapeutics, Inc. |
B7-h4 antibody formulations
|
WO2019165122A1
(en)
|
2018-02-21 |
2019-08-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
BR112020016990A2
(pt)
|
2018-02-21 |
2021-02-23 |
Five Prime Therapeutics, Inc. |
regimes de dosagem de anticorpos contra b7-h4
|
SG11202007694UA
(en)
|
2018-02-21 |
2020-09-29 |
Genentech Inc |
DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS
|
JP7391027B2
(ja)
|
2018-02-26 |
2023-12-04 |
ジェネンテック, インコーポレイテッド |
抗tigit及び抗pd-l1アンタゴニスト抗体による治療のための投薬
|
AU2019228600A1
(en)
|
2018-03-02 |
2020-09-24 |
Five Prime Therapeutics, Inc. |
B7-H4 antibodies and methods of use thereof
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
CN111836643A
(zh)
|
2018-03-05 |
2020-10-27 |
学校法人埼玉医科大学 |
用于治疗或预防异位骨化的药物组合物
|
US11485782B2
(en)
|
2018-03-14 |
2022-11-01 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Anti-claudin 18.2 antibodies
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
KR20200132938A
(ko)
|
2018-03-15 |
2020-11-25 |
추가이 세이야쿠 가부시키가이샤 |
지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
|
KR20200135421A
(ko)
|
2018-03-21 |
2020-12-02 |
파이브 프라임 테라퓨틱스, 인크. |
산성 pH에서 VISTA에 결합하는 항체
|
BR112020018539A2
(pt)
|
2018-03-23 |
2020-12-29 |
Bristol-Myers Squibb Company |
Anticorpos contra mica e/ou micb e usos dos mesmos
|
US11958903B2
(en)
|
2018-03-30 |
2024-04-16 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies against LAG-3 and uses thereof
|
CA3095719A1
(en)
|
2018-03-30 |
2019-10-03 |
Toray Industries, Inc. |
Pharmaceutical composition for treatment and/or prevention of cancer
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
US11471489B2
(en)
|
2018-04-05 |
2022-10-18 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
EP3552631A1
(en)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antibody-drug conjugates and their uses for the treatment of cancer
|
JP2021520829A
(ja)
|
2018-04-18 |
2021-08-26 |
ゼンコア インコーポレイテッド |
IL−15/IL−15RA Fc融合タンパク質およびTIM−3抗原結合ドメインを含む、TIM−3標的化ヘテロ二量体融合タンパク質
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
WO2019213384A1
(en)
|
2018-05-03 |
2019-11-07 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
WO2019211472A1
(en)
|
2018-05-03 |
2019-11-07 |
Genmab B.V. |
Antibody variant combinations and uses thereof
|
SG11202011309SA
(en)
|
2018-05-14 |
2020-12-30 |
Werewolf Therapeutics Inc |
Activatable interleukin 12 polypeptides and methods of use thereof
|
MX2020012251A
(es)
|
2018-05-14 |
2021-04-28 |
Werewolf Therapeutics Inc |
Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
|
EP4249002A3
(en)
|
2018-05-18 |
2023-11-22 |
Daiichi Sankyo Co., Ltd. |
Anti-muc1- exatecan antibody-drug conjugate
|
US20200109195A1
(en)
|
2018-05-21 |
2020-04-09 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
KR20210014660A
(ko)
|
2018-05-28 |
2021-02-09 |
다이이찌 산쿄 가부시키가이샤 |
항 her2 항체-약물 콘쥬게이트 투여에 의한 her2 변이암의 치료
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
US11932681B2
(en)
|
2018-05-31 |
2024-03-19 |
Novartis Ag |
Hepatitis B antibodies
|
KR20210018192A
(ko)
|
2018-05-31 |
2021-02-17 |
다이이찌 산쿄 가부시키가이샤 |
항인간 tlr7 항체
|
US11987629B2
(en)
|
2018-06-01 |
2024-05-21 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and uses thereof for treating disease or condition
|
EP3802611A2
(en)
|
2018-06-01 |
2021-04-14 |
Novartis AG |
Binding molecules against bcma and uses thereof
|
WO2019234576A1
(en)
|
2018-06-03 |
2019-12-12 |
Lamkap Bio Beta Ltd. |
Bispecific antibodies against ceacam5 and cd47
|
WO2019235426A1
(ja)
|
2018-06-04 |
2019-12-12 |
中外製薬株式会社 |
細胞質内での半減期が変化した抗原結合分子
|
WO2019245991A1
(en)
|
2018-06-18 |
2019-12-26 |
Eureka Therapeutics, Inc. |
Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
|
TWI819011B
(zh)
|
2018-06-23 |
2023-10-21 |
美商建南德克公司 |
以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法
|
US11873337B2
(en)
|
2018-06-26 |
2024-01-16 |
Kyowa Kirin Co., Ltd. |
Antibody binding to cell adhesion molecule 3
|
WO2020004490A1
(ja)
|
2018-06-26 |
2020-01-02 |
協和キリン株式会社 |
コンドロイチン硫酸プロテオグリカン-5に結合する抗体
|
MA53094A
(fr)
|
2018-07-02 |
2021-05-12 |
Amgen Inc |
Protéine de liaison à l'antigène anti-steap1
|
KR20210030405A
(ko)
|
2018-07-09 |
2021-03-17 |
파이브 프라임 테라퓨틱스, 인크. |
Ilt4에 결합하는 항체
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
PE20210687A1
(es)
|
2018-07-11 |
2021-04-08 |
Bristol Myers Squibb Co |
Anticuerpos de union a vista a ph acido
|
JP2021524276A
(ja)
|
2018-07-13 |
2021-09-13 |
ゲンマブ エー/エス |
Cd38抗体のバリアントおよびその使用
|
WO2020012038A1
(en)
|
2018-07-13 |
2020-01-16 |
Genmab A/S |
Trogocytosis-mediated therapy using cd38 antibodies
|
JP2021530502A
(ja)
|
2018-07-18 |
2021-11-11 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト、代謝拮抗剤、及びプラチナ製剤で肺がんを治療する方法
|
EP3823673A4
(en)
|
2018-07-20 |
2022-05-11 |
Surface Oncology, Inc. |
ANTI-CD112R COMPOSITIONS AND METHODS
|
KR20210038904A
(ko)
|
2018-07-25 |
2021-04-08 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘쥬게이트의 효과적인 제조 방법
|
AU2019315177A1
(en)
|
2018-07-31 |
2021-02-25 |
Daiichi Sankyo Company, Limited |
Treatment of metastatic brain tumor by administration of antibody-drug conjugate
|
EP3831854A4
(en)
|
2018-08-03 |
2022-05-04 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN-BINDING MOLECULE WITH TWO LINKED ANTIGEN-BINDING DOMAINS
|
BR112021001750A2
(pt)
|
2018-08-06 |
2021-04-27 |
Daiichi Sankyo Company, Limited |
composição farmacêutica
|
CA3051549A1
(en)
|
2018-08-09 |
2020-02-09 |
Regeneron Pharmaceuticals, Inc. |
Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
|
SG10202106830VA
(en)
|
2018-08-10 |
2021-08-30 |
Chugai Pharmaceutical Co Ltd |
Anti-cd137 antigen-binding molecule and utilization thereof
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商23與我有限公司 |
抗il1rap抗體及其使用方法
|
JP7481255B2
(ja)
|
2018-08-23 |
2024-05-10 |
第一三共株式会社 |
抗体薬物複合体の感受性マーカー
|
JP2021534196A
(ja)
|
2018-08-23 |
2021-12-09 |
シージェン インコーポレイテッド |
抗tigit抗体
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
WO2020047389A1
(en)
|
2018-08-31 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
WO2020053742A2
(en)
|
2018-09-10 |
2020-03-19 |
Novartis Ag |
Anti-hla-hbv peptide antibodies
|
EP4268831A3
(en)
|
2018-09-12 |
2024-05-22 |
Fred Hutchinson Cancer Center |
Reducing cd33 expression to selectively protect therapeutic cells
|
AU2019339469A1
(en)
|
2018-09-13 |
2021-03-11 |
Immune-Onc Therapeutics, Inc. |
Novel LILRB4 antibodies and uses thereof
|
CN113396160A
(zh)
|
2018-09-19 |
2021-09-14 |
国家医疗保健研究所 |
治疗对免疫检查点疗法具有抗性的癌症的方法和药物组合物
|
AU2019342099A1
(en)
|
2018-09-19 |
2021-04-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
BR112021005246A2
(pt)
|
2018-09-20 |
2021-06-15 |
Daiichi Sankyo Company, Limited |
agente terapêutico, e, método de tratamento para câncer
|
US20220322655A1
(en)
|
2018-09-20 |
2022-10-13 |
Iovance Biotherapeutics, Inc. |
Expansion of TILs from Cryopreserved Tumor Samples
|
ES2955032T3
(es)
|
2018-09-21 |
2023-11-28 |
Hoffmann La Roche |
Métodos de diagnóstico para el cáncer de mama triple negativo
|
EP3626265A1
(en)
|
2018-09-21 |
2020-03-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-human cd45rc antibodies and uses thereof
|
US20220002370A1
(en)
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
EP3858994A4
(en)
|
2018-09-28 |
2022-06-22 |
Kyowa Kirin Co., Ltd. |
ANTIBODY COMPOSITION
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
KR20210074286A
(ko)
|
2018-10-05 |
2021-06-21 |
파이브 프라임 테라퓨틱스, 인크. |
항-fgfr2 항체 제형
|
CN113164780A
(zh)
|
2018-10-10 |
2021-07-23 |
泰洛斯治疗公司 |
抗lap抗体变体及其用途
|
MX2021004226A
(es)
|
2018-10-15 |
2021-07-15 |
Five Prime Therapeutics Inc |
Terapia combinada contra el cáncer.
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
CA3116324A1
(en)
|
2018-10-18 |
2020-04-23 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
WO2020089437A1
(en)
|
2018-10-31 |
2020-05-07 |
Engmab Sàrl |
Combination therapy
|
WO2020089811A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
JP2022512899A
(ja)
|
2018-11-05 |
2022-02-07 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
抗pd-1抗体に対して不応性のnsclc患者の治療
|
MX2021004775A
(es)
|
2018-11-05 |
2021-06-08 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
|
JP2022512860A
(ja)
|
2018-11-06 |
2022-02-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
白血病幹細胞を根絶することによる急性骨髄性白血病の治療のための方法および医薬組成物
|
CA3119161A1
(en)
|
2018-11-13 |
2020-05-22 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
CA3119956A1
(en)
|
2018-11-14 |
2020-05-22 |
Daiichi Sankyo Company, Limited |
Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
|
CN113366022A
(zh)
|
2018-11-16 |
2021-09-07 |
纪念斯隆凯特琳癌症中心 |
针对粘蛋白-16的抗体及其使用方法
|
JP2022513653A
(ja)
|
2018-11-28 |
2022-02-09 |
ブリストル-マイヤーズ スクイブ カンパニー |
修飾された重鎖定常領域を含む抗体
|
JP2022511502A
(ja)
|
2018-12-05 |
2022-01-31 |
ジェネンテック, インコーポレイテッド |
がんの免疫療法のための診断方法及び診断用組成物
|
KR20210100668A
(ko)
|
2018-12-06 |
2021-08-17 |
제넨테크, 인크. |
항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
|
EP3894427A1
(en)
|
2018-12-10 |
2021-10-20 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
CN113271942A
(zh)
|
2018-12-11 |
2021-08-17 |
第一三共株式会社 |
抗体-药物缀合物与parp抑制剂的组合
|
WO2020120786A1
(en)
|
2018-12-14 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8+cd45rclow tregs
|
TW202039554A
(zh)
|
2018-12-19 |
2020-11-01 |
瑞士商諾華公司 |
抗TNF-α抗體
|
EP3883609A2
(en)
|
2018-12-20 |
2021-09-29 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
EP3898667A2
(en)
|
2018-12-20 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Modified antibody fcs and methods of use
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
AR123405A1
(es)
|
2018-12-21 |
2022-11-30 |
23Andme Inc |
Anticuerpos anti-il-36 y métodos de uso de estos
|
AU2019407426A1
(en)
|
2018-12-21 |
2021-07-22 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugate and kinase inhibitor
|
KR20210142594A
(ko)
|
2018-12-26 |
2021-11-25 |
시티 오브 호프 |
활성화 가능한 차폐된 항-ctla4 결합 단백질
|
KR20210108961A
(ko)
|
2018-12-28 |
2021-09-03 |
쿄와 기린 가부시키가이샤 |
TfR에 결합하는 이중 특이적 항체
|
EP3902830A1
(en)
|
2018-12-30 |
2021-11-03 |
F. Hoffmann-La Roche AG |
Anti-rabbit cd19 antibodies and methods of use
|
WO2020146740A1
(en)
|
2019-01-10 |
2020-07-16 |
Iovance Biotherapeutics, Inc. |
System and methods for monitoring adoptive cell therapy clonality and persistence
|
WO2020148207A1
(en)
|
2019-01-14 |
2020-07-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies binding to hla-a2
|
WO2020150152A1
(en)
|
2019-01-14 |
2020-07-23 |
Genentech, Inc. |
Methods of treating cancer with a pd-1 axis binding antagonist and an rna vaccine
|
CN109762067B
(zh)
|
2019-01-17 |
2020-02-28 |
北京天广实生物技术股份有限公司 |
结合人Claudin 18.2的抗体及其用途
|
KR20230128134A
(ko)
|
2019-01-22 |
2023-09-01 |
브리스톨-마이어스 스큅 컴퍼니 |
Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
|
JP2022523047A
(ja)
|
2019-01-23 |
2022-04-21 |
エンセファ |
Cd31競合剤およびその使用
|
WO2020153467A1
(ja)
|
2019-01-24 |
2020-07-30 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
CN113365660A
(zh)
|
2019-01-29 |
2021-09-07 |
朱诺治疗学股份有限公司 |
对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
JP2022521773A
(ja)
|
2019-02-27 |
2022-04-12 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬
|
WO2020180733A1
(en)
|
2019-03-01 |
2020-09-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
KR20210134725A
(ko)
|
2019-03-01 |
2021-11-10 |
젠코어 인코포레이티드 |
Enpp3과 cd3에 결합하는 이종이량체 항체
|
TW202101000A
(zh)
|
2019-03-08 |
2021-01-01 |
美商建南德克公司 |
用於偵測且量化膜相關蛋白之方法
|
CN113631578A
(zh)
|
2019-03-14 |
2021-11-09 |
豪夫迈·罗氏有限公司 |
用her2xcd3双特异性抗体联合抗her2 mab治疗癌症
|
EP3943108A4
(en)
|
2019-03-19 |
2023-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN-BINDING MOLECULE CONTAINING AN ANTIGEN-BINDING DOMAIN WHOSE ANTIGEN-BINDING ACTIVITY IS ALTERED DEPENDING ON THE MTA, AND BANK FOR OBTAINING SUCH ANTIGEN-BINDING DOMAIN
|
AU2020246448A1
(en)
|
2019-03-25 |
2021-10-14 |
Daiichi Sankyo Company, Limited |
Anti-HER2 antibody-pyrrolobenzodiazepine derivative conjugate
|
EP3950061A4
(en)
|
2019-03-25 |
2022-11-16 |
Daiichi Sankyo Company, Limited |
ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
|
US20220168438A1
(en)
|
2019-03-27 |
2022-06-02 |
Daiichi Sankyo Company, Limited |
Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
|
WO2020198731A2
(en)
|
2019-03-28 |
2020-10-01 |
Danisco Us Inc |
Engineered antibodies
|
EP3955960A1
(en)
|
2019-04-18 |
2022-02-23 |
Bristol-Myers Squibb Company |
Ipilimumab variants with enhanced specificity for binding at low ph
|
BR112021019571A2
(pt)
|
2019-04-19 |
2021-12-07 |
Chugai Pharmaceutical Co Ltd |
Receptor quimérico que reconhece o sítio de modificação do anticorpo
|
BR112021020867A2
(pt)
|
2019-04-19 |
2022-01-04 |
Genentech Inc |
Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração
|
CN114269376A
(zh)
|
2019-05-03 |
2022-04-01 |
豪夫迈·罗氏有限公司 |
用抗pd-l1抗体治疗癌症的方法
|
EP3962523A2
(en)
|
2019-05-03 |
2022-03-09 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
JP2022536602A
(ja)
|
2019-05-14 |
2022-08-18 |
ジェネンテック, インコーポレイテッド |
濾胞性リンパ腫を処置するための抗cd79b免疫複合体の使用方法
|
SG11202112541RA
(en)
|
2019-05-14 |
2021-12-30 |
Werewolf Therapeutics Inc |
Separation moieties and methods and use thereof
|
TW202108625A
(zh)
|
2019-05-15 |
2021-03-01 |
日商協和麒麟股份有限公司 |
與cd40及gpc3結合之雙專一性抗體
|
EP3970743A4
(en)
|
2019-05-15 |
2023-02-15 |
Kyowa Kirin Co., Ltd. |
BISPECIFIC ANTIBODIES BINDING TO CD40 AND FAP
|
JP2022533215A
(ja)
|
2019-05-20 |
2022-07-21 |
ノバルティス アーゲー |
親水性基を含むリンカーを有する抗体薬剤コンジュゲート
|
WO2020234399A1
(en)
|
2019-05-20 |
2020-11-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Novel anti-cd25 antibodies
|
WO2020236795A2
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Trispecific binding molecules against bcma and uses thereof
|
MX2021014164A
(es)
|
2019-05-21 |
2022-01-04 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas.
|
US20230085439A1
(en)
|
2019-05-21 |
2023-03-16 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
WO2020236797A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Variant cd58 domains and uses thereof
|
MX2021014274A
(es)
|
2019-05-23 |
2022-01-06 |
Ac Immune Sa |
Moleculas de union anti-tdp-43 y usos de las mismas.
|
AU2020285681A1
(en)
|
2019-05-29 |
2022-01-27 |
Daiichi Sankyo Company, Limited |
Dosage of an antibody-drug conjugate
|
CN113966345A
(zh)
|
2019-06-12 |
2022-01-21 |
诺华股份有限公司 |
利钠肽受体1抗体及使用方法
|
JP2022539178A
(ja)
|
2019-06-26 |
2022-09-07 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
Il1rap結合タンパク質
|
CN114269783B
(zh)
|
2019-07-02 |
2024-03-26 |
美国政府(由卫生和人类服务部的部长所代表) |
结合egfrviii的单克隆抗体及其应用
|
EP3998083A4
(en)
|
2019-07-12 |
2023-08-23 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-MUTATION TYPE FGFR3 ANTIBODY AND USE THEREOF
|
US20220251208A1
(en)
|
2019-07-15 |
2022-08-11 |
Intervet Inc. |
Caninized Antibodies Against Canine CTLA-4
|
AU2020312687A1
(en)
|
2019-07-15 |
2022-01-27 |
Intervet International B.V. |
Caninized antibodies to human and canine CTLA-4
|
WO2021009263A1
(en)
|
2019-07-16 |
2021-01-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity for cd38 and uses thereof
|
US20220306734A1
(en)
|
2019-07-24 |
2022-09-29 |
H. Lundbeck A/S |
Anti-mglur5 antibodies and uses thereof
|
EP4008350A4
(en)
|
2019-07-26 |
2023-06-14 |
Saitama Medical University |
ANTIBODY RECOGNIZING THE EXTRACELLULAR REGION OF ALK2/ACVR1
|
JP2022542505A
(ja)
|
2019-07-29 |
2022-10-04 |
コンピュジェン リミテッド |
抗pvrig抗体製剤およびそれらの使用
|
US20220289859A1
(en)
|
2019-08-06 |
2022-09-15 |
Glaxosmithkline Intellectual Property Development Limited |
Biopharmacuetical Compositions and Related Methods
|
CN114641490B
(zh)
|
2019-08-06 |
2023-06-06 |
新旭生技股份有限公司 |
结合至病理性tau种类的抗体及其用途
|
WO2021050645A1
(en)
|
2019-09-12 |
2021-03-18 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
US20220348651A1
(en)
|
2019-09-18 |
2022-11-03 |
Novartis Ag |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
US20230192860A1
(en)
|
2019-09-19 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies Binding to Vista at Acidic pH
|
CR20220149A
(es)
|
2019-09-20 |
2022-05-23 |
Genentech Inc |
Dosis para anticuerpos anti-triptasa
|
TW202126688A
(zh)
|
2019-09-27 |
2021-07-16 |
瑞典商阿斯特捷利康公司 |
使用貝那利珠單抗治療遲發性氣喘之方法
|
CR20220127A
(es)
|
2019-09-27 |
2022-05-27 |
Genentech Inc |
Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
|
WO2021064184A1
(en)
|
2019-10-04 |
2021-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
|
WO2021074695A1
(en)
|
2019-10-16 |
2021-04-22 |
Avacta Life Sciences Limited |
PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
|
AU2020365836A1
(en)
|
2019-10-18 |
2022-04-28 |
F. Hoffmann-La Roche Ag |
Methods of using anti-CD79b immunoconjugates to treat diffuse large B-cell lymphoma
|
BR112022008558A2
(pt)
|
2019-11-04 |
2022-08-09 |
Compugen Ltd |
Método de tratamento para câncer, tratamento de combinação de nivolumabe e anticorpos anti-pvrig, e, uso
|
JP2022553803A
(ja)
|
2019-11-06 |
2022-12-26 |
ジェネンテック, インコーポレイテッド |
血液がんの処置のための診断方法及び治療方法
|
EP4062933A4
(en)
|
2019-11-20 |
2023-12-13 |
Chugai Seiyaku Kabushiki Kaisha |
PHARMACEUTICAL PREPARATION COMPRISING AN ANTIBODY
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
JP2023504740A
(ja)
|
2019-12-06 |
2023-02-06 |
ジュノー セラピューティクス インコーポレイテッド |
Bcma標的結合ドメインに対する抗イディオタイプ抗体ならびに関連する組成物および方法
|
CN115335399A
(zh)
|
2019-12-06 |
2022-11-11 |
朱诺治疗学股份有限公司 |
针对gprc5d靶结合结构域的抗独特型抗体以及相关组合物和方法
|
US20230040928A1
(en)
|
2019-12-09 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
EP4072584A1
(en)
|
2019-12-13 |
2022-10-19 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
WO2021123092A1
(en)
|
2019-12-20 |
2021-06-24 |
Intervet International B.V. |
Bispecific caninized antibodies for treating atopic dermatitis
|
MX2022007672A
(es)
|
2019-12-20 |
2022-07-19 |
Intervet Int Bv |
Anticuerpos del receptor alfa de interleucina-4 canina.
|
US20230075422A1
(en)
|
2019-12-20 |
2023-03-09 |
Bristol-Myers Squibb Company |
Use of fucosylation inhibitor for producing afucosylated antibody
|
AR120898A1
(es)
|
2019-12-26 |
2022-03-30 |
Univ Osaka |
Agente para tratar o prevenir neuromielitis óptica en fase aguda
|
CN110964090B
(zh)
*
|
2019-12-26 |
2021-02-19 |
江南大学 |
一种促进n-乙酰氨基葡萄糖生产的蛋白质起始因子if3突变体及其应用
|
CN113045655A
(zh)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
抗ox40抗体及其用途
|
MX2022007840A
(es)
|
2019-12-27 |
2022-07-19 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti antigeno-4 asociado al linfocito t citotoxico (ctla4) y uso del mismo.
|
TW202138388A
(zh)
|
2019-12-30 |
2021-10-16 |
美商西根公司 |
以非海藻糖苷化抗-cd70抗體治療癌症之方法
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
CN114945385A
(zh)
|
2020-01-15 |
2022-08-26 |
国立大学法人大阪大学 |
痴呆症的预防或治疗剂
|
EP4090366A1
(en)
|
2020-01-16 |
2022-11-23 |
Genmab A/S |
Formulations of cd38 antibodies and uses thereof
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
JP2023512654A
(ja)
|
2020-01-31 |
2023-03-28 |
ジェネンテック, インコーポレイテッド |
Pd-1軸結合アンタゴニストおよびrnaワクチンを用いてネオエピトープ特異的t細胞を誘導する方法
|
WO2021155295A1
(en)
|
2020-01-31 |
2021-08-05 |
The Cleveland Clinic Foundation |
Anti-müllerian hormone receptor 2 antibodies and methods of use
|
IL295387A
(en)
|
2020-02-05 |
2022-10-01 |
Larimar Therapeutics Inc |
Peptide-binding proteins and their uses
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
TW202140561A
(zh)
|
2020-02-14 |
2021-11-01 |
日商協和麒麟股份有限公司 |
與cd3結合之雙特異性抗體
|
TWI832035B
(zh)
|
2020-02-14 |
2024-02-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
US20230348568A1
(en)
|
2020-02-20 |
2023-11-02 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Epstein-barr virus monoclonal antibodies and uses thereof
|
MX2022010665A
(es)
|
2020-02-27 |
2022-09-23 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos.
|
KR20220148209A
(ko)
|
2020-02-28 |
2022-11-04 |
상하이 헨리우스 바이오테크, 인크. |
항cd137 작제물 및 그 용도
|
WO2021170071A1
(en)
|
2020-02-28 |
2021-09-02 |
Shanghai Henlius Biotech, Inc. |
Anti-cd137 constructs, multispecific antibody and uses thereof
|
JPWO2021182573A1
(da)
|
2020-03-12 |
2021-09-16 |
|
|
EP4119160A4
(en)
|
2020-03-12 |
2024-04-03 |
Toray Industries |
MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
|
EP4119159A4
(en)
|
2020-03-12 |
2024-03-27 |
Toray Industries |
MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
|
CA3175127A1
(en)
|
2020-03-12 |
2021-09-16 |
Toray Industries, Inc. |
Medicament for treatment and/or prevention of cancer
|
WO2021182570A1
(ja)
|
2020-03-12 |
2021-09-16 |
東レ株式会社 |
癌の治療及び/又は予防のための医薬品
|
US11760797B2
(en)
|
2020-03-13 |
2023-09-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
IL296427A
(en)
|
2020-03-19 |
2022-11-01 |
Genentech Inc |
Isoform-selective anti-tgf antibodies and methods of use
|
EP4126950A1
(en)
|
2020-03-23 |
2023-02-08 |
Bristol-Myers Squibb Company |
Anti-ccr8 antibodies for treating cancer
|
IL296528A
(en)
|
2020-03-24 |
2022-11-01 |
Genentech Inc |
Tie2 binding agents and methods of use
|
EP4126241A1
(en)
|
2020-03-27 |
2023-02-08 |
Novartis AG |
Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
|
EP4144370A4
(en)
|
2020-03-30 |
2024-05-15 |
Univ Mie |
BISPECIFIC ANTIBODY
|
AU2021249888A1
(en)
|
2020-04-01 |
2022-10-27 |
Kyowa Kirin Co., Ltd. |
Antibody composition
|
EP4126934A1
(en)
|
2020-04-01 |
2023-02-08 |
University of Rochester |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
JP2023520515A
(ja)
|
2020-04-03 |
2023-05-17 |
ジェネンテック, インコーポレイテッド |
がんに対する治療方法及び診断方法
|
US20230272056A1
(en)
|
2020-04-09 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Affinity matured anti-lap antibodies and uses thereof
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
EP4139359A1
(en)
|
2020-04-24 |
2023-03-01 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
AU2021262744A1
(en)
|
2020-04-27 |
2022-10-06 |
The Regents Of The University Of California |
Isoform-independent antibodies to lipoprotein(a)
|
US11634477B2
(en)
|
2020-04-28 |
2023-04-25 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
|
EP4143345A1
(en)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
CA3176894A1
(en)
|
2020-04-30 |
2021-11-04 |
Marco DE BRUYN |
Anti-cd103 antibodies
|
IL297830A
(en)
|
2020-05-03 |
2023-01-01 |
Levena Suzhou Biopharma Co Ltd |
Anti-drug compounds (adcs) comprising an anti-trop-2 antibody, compounds comprising such adcs, as well as methods for their production and use
|
MX2022014243A
(es)
|
2020-05-12 |
2022-12-02 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Proteina de union al antigeno st2.
|
US20230181753A1
(en)
|
2020-05-12 |
2023-06-15 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
CN115697491A
(zh)
|
2020-05-17 |
2023-02-03 |
阿斯利康(英国)有限公司 |
Sars-cov-2抗体及其选择和使用方法
|
JP2023527352A
(ja)
|
2020-05-26 |
2023-06-28 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗sars-cov-2-スパイク糖タンパク質抗体及び抗原結合断片
|
WO2021238886A1
(en)
|
2020-05-27 |
2021-12-02 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing nerve growth factor and uses thereof
|
AU2021281417A1
(en)
|
2020-05-29 |
2022-12-08 |
23Andme, Inc. |
Anti-CD200R1 antibodies and methods of use thereof
|
TW202210515A
(zh)
|
2020-06-02 |
2022-03-16 |
美商當康生物科技有限公司 |
抗cd39之構築體及其用途
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
JP2023528441A
(ja)
|
2020-06-03 |
2023-07-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗SARS-CoV-2スパイク糖タンパク質抗体を用いてSARS-CoV-2感染及びCOVID-19を治療又は予防するための方法
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
JP2023529206A
(ja)
|
2020-06-12 |
2023-07-07 |
ジェネンテック, インコーポレイテッド |
がん免疫療法のための方法及び組成物
|
WO2021257503A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
MX2022015881A
(es)
|
2020-06-18 |
2023-01-24 |
Genentech Inc |
Tratamiento con anticuerpos anti-tigit y antagonistas de union al eje de pd-1.
|
JP2023531222A
(ja)
|
2020-06-22 |
2023-07-21 |
アルミラル・ソシエダッド・アノニマ |
抗il-36抗体およびその使用方法
|
CN116670285A
(zh)
|
2020-06-23 |
2023-08-29 |
江苏康缘药业股份有限公司 |
抗cd38抗体及其用途
|
TW202216759A
(zh)
|
2020-06-25 |
2022-05-01 |
美商默沙東藥廠 |
靶向絲胺酸413經磷酸化之tau之高親和力抗體
|
TW202214697A
(zh)
|
2020-06-30 |
2022-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗cd70抗體及其應用
|
BR112023000711A2
(pt)
|
2020-07-17 |
2023-01-31 |
Daiichi Sankyo Co Ltd |
Método para produzir uma composição de conjugado de anticorpo-fármaco, e, composição de conjugado de anticorpo-fármaco
|
US20230293714A1
(en)
|
2020-07-20 |
2023-09-21 |
Daiichi Sankyo Company, Limited |
Combination of anti-her2 antibody-drug conjugate with her dimerization inhibitor
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
KR20230133832A
(ko)
|
2020-07-29 |
2023-09-19 |
다이내믹큐어 바이오테크놀로지 엘엘씨 |
항-cd93 구축물 및 그의 용도
|
CN116568824A
(zh)
|
2020-08-03 |
2023-08-08 |
基因泰克公司 |
淋巴瘤的诊断和治疗方法
|
WO2022029080A1
(en)
|
2020-08-03 |
2022-02-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
KR20230095918A
(ko)
|
2020-08-05 |
2023-06-29 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법
|
AR123158A1
(es)
|
2020-08-07 |
2022-11-02 |
Genentech Inc |
Proteínas de fusión del ligando para flt3 y métodos de uso
|
IL300257A
(en)
|
2020-08-10 |
2023-03-01 |
Astrazeneca Uk Ltd |
SARS-COV-2 antibodies for the treatment and prevention of COVID-19
|
US20230416364A1
(en)
|
2020-08-13 |
2023-12-28 |
Bristol-Myers Squibb Company |
Methods of redirecting of il-2 to target cells of interest
|
US20230322908A1
(en)
|
2020-08-14 |
2023-10-12 |
Ac Immune Sa |
Humanized Anti-TDP-43 Binding Molecules and Uses Thereof
|
KR20230166150A
(ko)
|
2020-08-19 |
2023-12-06 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
EP4204448A2
(en)
|
2020-08-27 |
2023-07-05 |
cureab GmbH |
Anti-golph2 antibodies for macrophage and dendritic cell differentiation
|
CN116096411A
(zh)
|
2020-09-01 |
2023-05-09 |
中外制药株式会社 |
含有作为活性成分的il-31拮抗剂的用于预防和/或治疗透析瘙痒的药物组合物
|
JP2023541627A
(ja)
|
2020-09-14 |
2023-10-03 |
イシュノス サイエンシズ ソシエテ アノニム |
Il1rapに結合する抗体及びその使用
|
KR20230104611A
(ko)
|
2020-09-30 |
2023-07-10 |
드렌 바이오, 인크. |
항-cd94 항체 및 이의 사용 방법
|
WO2022069940A1
(en)
|
2020-09-30 |
2022-04-07 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
|
TWI836278B
(zh)
|
2020-10-05 |
2024-03-21 |
美商建南德克公司 |
用抗fcrh5/抗cd3雙特異性抗體進行治療之給藥
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
UY39467A
(es)
|
2020-10-13 |
2022-04-29 |
Janssen Biotech Inc |
Inmunidad mediada por células t de bioingeniería, materiales y otros métodos para modular el grupo de diferenciación iv y / o viii
|
WO2022081718A1
(en)
|
2020-10-14 |
2022-04-21 |
Five Prime Therapeutics, Inc. |
Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
|
CA3192306A1
(en)
|
2020-10-20 |
2022-04-28 |
Burkhard Ludewig |
Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
|
CN116685325A
(zh)
|
2020-10-20 |
2023-09-01 |
豪夫迈·罗氏有限公司 |
Pd-1轴结合拮抗剂和lrrk2抑制剂的组合疗法
|
EP4232822A2
(en)
|
2020-10-26 |
2023-08-30 |
Compugen Ltd. |
Pvrl2 and/or pvrig as biomarkers for treatment
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
AR123997A1
(es)
|
2020-11-04 |
2023-02-01 |
Univ Rockefeller |
ANTICUERPOS NEUTRALIZANTES CONTRA EL SARS-CoV-2
|
WO2022098638A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
MX2023005130A
(es)
|
2020-11-04 |
2023-05-25 |
Genentech Inc |
Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3.
|
WO2022098648A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
CN116390949A
(zh)
|
2020-11-06 |
2023-07-04 |
百时美施贵宝公司 |
作为单一疗法给药和施用非岩藻糖基化抗ctla-4抗体
|
US20240025993A1
(en)
|
2020-11-06 |
2024-01-25 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
EP4240494A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
|
KR20230106645A
(ko)
|
2020-11-11 |
2023-07-13 |
다이이찌 산쿄 가부시키가이샤 |
항체-약물 콘주게이트와 항 SIRPα 항체의 조합
|
US20230398230A1
(en)
|
2020-11-12 |
2023-12-14 |
Daiichi Sankyo Company, Limited |
Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate
|
EP4247496A1
(en)
|
2020-11-20 |
2023-09-27 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Anti-cd25 antibodies
|
KR20230118108A
(ko)
|
2020-11-20 |
2023-08-10 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
항-cd25 항체
|
TW202237639A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
TW202241468A
(zh)
|
2020-12-11 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
用腫瘤浸潤性淋巴球療法與braf抑制劑及/或mek抑制劑組合治療癌症患者
|
EP4259661A1
(en)
|
2020-12-14 |
2023-10-18 |
Novartis AG |
Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
CA3202483A1
(en)
|
2020-12-17 |
2022-06-23 |
Maria Fardis |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
WO2022133149A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
IL303922A
(en)
|
2020-12-23 |
2023-08-01 |
Cantargia Ab |
Anti-IL1RAP antibody
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
CN114685669A
(zh)
|
2020-12-30 |
2022-07-01 |
和铂医药(苏州)有限公司 |
结合trop2的抗体及其用途
|
TW202242085A
(zh)
|
2020-12-31 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
供自動生產腫瘤浸潤淋巴球的裝置和方法
|
JP2024503394A
(ja)
|
2021-01-08 |
2024-01-25 |
北京韓美薬品有限公司 |
4-1bbと特異的に結合する抗体及びその抗原結合フラグメント
|
JP2024503396A
(ja)
|
2021-01-08 |
2024-01-25 |
北京韓美薬品有限公司 |
Cd47と特異的に結合する抗体及びその抗原結合フラグメント
|
TW202245844A
(zh)
|
2021-01-13 |
2022-12-01 |
紀念斯隆凱特琳癌症中心 |
抗dll3抗體-藥物結合物
|
EP4277664A1
(en)
|
2021-01-13 |
2023-11-22 |
Memorial Sloan Kettering Cancer Center |
Antibody-pyrrolobenzodiazepine derivative conjugate
|
JP2024505636A
(ja)
|
2021-01-15 |
2024-02-07 |
ザ ロックフェラー ユニバーシティー |
抗sars-cov-2中和抗体
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
EP4284516A1
(en)
|
2021-01-28 |
2023-12-06 |
Compugen Ltd. |
Anti-pvrig antibodies formulations and uses thereof
|
WO2022162203A1
(en)
|
2021-01-28 |
2022-08-04 |
Vaccinvent Gmbh |
Method and means for modulating b-cell mediated immune responses
|
WO2022165275A2
(en)
|
2021-01-28 |
2022-08-04 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies
|
CN117120084A
(zh)
|
2021-01-28 |
2023-11-24 |
维肯芬特有限责任公司 |
用于调节b细胞介导的免疫应答的方法和手段
|
EP4284422A1
(en)
|
2021-01-28 |
2023-12-06 |
Vaccinvent GmbH |
Method and means for modulating b-cell mediated immune responses
|
JP2024506557A
(ja)
|
2021-01-29 |
2024-02-14 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
修飾された腫瘍浸潤リンパ球を作製する方法及び養子細胞療法におけるそれらの使用
|
EP4291306A1
(en)
|
2021-02-09 |
2023-12-20 |
University of Georgia Research Foundation, Inc. |
Human monoclonal antibodies against pneumococcal antigens
|
KR20230142790A
(ko)
|
2021-02-09 |
2023-10-11 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
코로나바이러스 스파이크 단백질(spike protein)을 타겟팅하는 항체
|
MX2023009497A
(es)
|
2021-02-15 |
2023-08-23 |
Takeda Pharmaceuticals Co |
Composiciones y metodos de terapia celular para modular la se?alizacion del factor de crecimiento transformador-beta (tgf-beta).
|
AR124914A1
(es)
|
2021-02-18 |
2023-05-17 |
Mitsubishi Tanabe Pharma Corp |
Nuevo anticuerpo anti-pad4
|
US20220378929A1
(en)
|
2021-02-25 |
2022-12-01 |
MediBoston Limted |
Anti-her2 antibody-drug conjugates and uses thereof
|
US20220306743A1
(en)
|
2021-03-01 |
2022-09-29 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
TW202246324A
(zh)
|
2021-03-01 |
2022-12-01 |
美商艾希利歐發展股份有限公司 |
用於治療癌症的經掩蔽之ctla4及pd1/pdl1抗體之組合
|
CA3210069A1
(en)
|
2021-03-03 |
2022-09-09 |
Tong Zhu |
Antibody-drug conjugates comprising an anti-bcma antibody
|
CN117279506A
(zh)
|
2021-03-05 |
2023-12-22 |
艾欧凡斯生物治疗公司 |
肿瘤储存及细胞培养组合物
|
JP2024509191A
(ja)
|
2021-03-05 |
2024-02-29 |
ダイナミキュア バイオテクノロジー エルエルシー |
抗vista構築物およびその使用
|
KR20230156079A
(ko)
|
2021-03-09 |
2023-11-13 |
젠코어 인코포레이티드 |
Cd3과 cldn6에 결합하는 이종이량체 항체
|
KR20230148226A
(ko)
|
2021-03-10 |
2023-10-24 |
이뮤노웨이크 인크. |
면역조절 분자 및 이의 용도
|
US11859012B2
(en)
|
2021-03-10 |
2024-01-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and GPC3
|
MX2023010812A
(es)
|
2021-03-15 |
2023-09-27 |
Genentech Inc |
Composiciones y metodos para tratar la nefritis lupica.
|
US20220306754A1
(en)
|
2021-03-18 |
2022-09-29 |
Medimmune Limited |
Therapeutic binding molecules
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
US20240191191A1
(en)
|
2021-03-19 |
2024-06-13 |
Iovance Biotherapeutics, Inc. |
Methods for infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
WO2022204155A1
(en)
|
2021-03-23 |
2022-09-29 |
Iovance Biotherapeutics, Inc. |
Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
KR20240012352A
(ko)
|
2021-03-23 |
2024-01-29 |
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) |
T 세포 림프종의 진단 및 치료 방법
|
US20220313806A1
(en)
|
2021-03-25 |
2022-10-06 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for t-cell coculture potency assays and use with cell therapy products
|
US20240150466A1
(en)
|
2021-03-25 |
2024-05-09 |
Dynamicure Biotechnology Llc |
Anti-igfbp7 constructs and uses thereof
|
BR112023019138A2
(pt)
|
2021-03-26 |
2023-10-24 |
Innate Pharma |
Proteína multiespecífica, composição farmacêutica, célula recombinante, método de preparação de uma composição de célula nk, composição de células nk, uso de uma proteína ou composição, métodos e uso
|
WO2022210485A1
(ja)
|
2021-03-29 |
2022-10-06 |
第一三共株式会社 |
安定な多重特異性分子及びその利用
|
WO2022214681A1
(en)
|
2021-04-09 |
2022-10-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of anaplastic large cell lymphoma
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
KR20240037185A
(ko)
|
2021-04-19 |
2024-03-21 |
이오반스 바이오테라퓨틱스, 인크. |
키메라 공동자극 수용체, 케모카인 수용체, 및 세포 면역치료에서의 이의 용도
|
JP2024514281A
(ja)
|
2021-04-23 |
2024-04-01 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Nk細胞係合剤関連の有害作用の防止または軽減
|
JP2024517535A
(ja)
|
2021-04-30 |
2024-04-23 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd20/抗cd3二重特異性抗体と抗cd79b抗体薬物コンジュゲートを用いた併用治療の投与
|
EP4334343A2
(en)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
JP2024520901A
(ja)
|
2021-05-12 |
2024-05-27 |
ジェネンテック, インコーポレイテッド |
びまん性大細胞型b細胞リンパ腫を治療するための抗cd79bイムノコンジュゲートを使用する方法
|
JP2024518545A
(ja)
|
2021-05-14 |
2024-05-01 |
ジェネンテック, インコーポレイテッド |
Trem2のアゴニスト
|
WO2022245859A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
WO2022245877A1
(en)
|
2021-05-17 |
2022-11-24 |
Curia Ip Holdings, Llc |
Sars-cov-2 spike protein antibodies
|
EP4340850A1
(en)
|
2021-05-17 |
2024-03-27 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
CN117396513A
(zh)
|
2021-05-28 |
2024-01-12 |
葛兰素史密斯克莱知识产权发展有限公司 |
治疗癌症的联合疗法
|
EP4155321A1
(en)
|
2021-06-04 |
2023-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
TW202317614A
(zh)
|
2021-06-07 |
2023-05-01 |
美商安進公司 |
使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
|
WO2022258691A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
|
JP2024521405A
(ja)
|
2021-06-09 |
2024-05-31 |
イナート・ファルマ・ソシエテ・アノニム |
Nkp46、サイトカイン受容体、腫瘍抗原およびcd16aに結合する多特異性タンパク質
|
CA3227227A1
(en)
|
2021-06-09 |
2022-12-15 |
Laurent Gauthier |
Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
|
WO2022258678A1
(en)
|
2021-06-09 |
2022-12-15 |
Innate Pharma |
Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
|
EP4351582A1
(en)
|
2021-06-09 |
2024-04-17 |
F. Hoffmann-La Roche AG |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
WO2022266660A1
(en)
|
2021-06-17 |
2022-12-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
JP2023535884A
(ja)
|
2021-06-22 |
2023-08-22 |
ノバルティス アーゲー |
化膿性汗腺炎の処置における使用のための二特異性抗体
|
JPWO2022270524A1
(da)
|
2021-06-23 |
2022-12-29 |
|
|
WO2022270523A1
(ja)
|
2021-06-23 |
2022-12-29 |
東レ株式会社 |
癌の治療及び/又は予防のための医薬品
|
AU2022297107A1
(en)
|
2021-06-25 |
2024-01-18 |
Chugai Seiyaku Kabushiki Kaisha |
Use of anti-ctla-4 antibody
|
CA3221833A1
(en)
|
2021-06-25 |
2022-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ctla-4 antibody
|
WO2023278377A1
(en)
|
2021-06-29 |
2023-01-05 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
EP4363450A1
(en)
|
2021-07-01 |
2024-05-08 |
Compugen Ltd. |
Anti-tigit and anti-pvrig in monotherapy and combination treatments
|
TW202317633A
(zh)
|
2021-07-08 |
2023-05-01 |
美商舒泰神(加州)生物科技有限公司 |
特異性識別tnfr2的抗體及其用途
|
BR112024000744A2
(pt)
|
2021-07-14 |
2024-04-30 |
Regeneron Pharma |
Anticorpos de glicoprotéina spike anti-sars-cov-2 e fragmentos de ligação a antígeno
|
KR20240058075A
(ko)
|
2021-07-14 |
2024-05-03 |
스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 |
Cd40을 특이적으로 식별하는 항체 및 이의 응용
|
TW202317635A
(zh)
|
2021-07-14 |
2023-05-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
特異性結合hgfr和egfr的抗原結合分子及其醫藥用途
|
CA3226111A1
(en)
|
2021-07-22 |
2023-01-26 |
Iovance Biotherapeutics, Inc. |
Method for cryopreservation of solid tumor fragments
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
EP4378478A1
(en)
|
2021-07-27 |
2024-06-05 |
Toray Industries, Inc. |
Medicament for treatment and/or prevention of cancer
|
EP4378476A1
(en)
|
2021-07-27 |
2024-06-05 |
Toray Industries, Inc. |
Medicament for treatment and/or prevention of cancer
|
KR20240042415A
(ko)
|
2021-07-27 |
2024-04-02 |
도레이 카부시키가이샤 |
암의 치료 및/또는 예방을 위한 의약품
|
TW202327631A
(zh)
|
2021-07-28 |
2023-07-16 |
美商艾歐凡斯生物治療公司 |
利用腫瘤浸潤性淋巴球療法與kras抑制劑組合治療癌症患者
|
IL310392A
(en)
|
2021-08-03 |
2024-03-01 |
Glaxosmithkline Ip Dev Ltd |
Biopharmaceutical preparations and a peptide mapping method for stable isotope labeling
|
TW202337499A
(zh)
|
2021-08-07 |
2023-10-01 |
美商建南德克公司 |
使用抗cd79b免疫結合物治療瀰漫性大b細胞淋巴瘤之方法
|
EP4384553A1
(en)
|
2021-08-13 |
2024-06-19 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
EP4384224A1
(en)
|
2021-08-13 |
2024-06-19 |
GlaxoSmithKline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras
|
CA3228243A1
(en)
|
2021-08-13 |
2023-02-16 |
Peiling CHEN |
Cytotoxicity targeting chimeras for ccr2-expressing cells
|
WO2023021055A1
(en)
|
2021-08-19 |
2023-02-23 |
F. Hoffmann-La Roche Ag |
Multivalent anti-variant fc-region antibodies and methods of use
|
WO2023027177A1
(ja)
|
2021-08-26 |
2023-03-02 |
協和キリン株式会社 |
Cd116およびcd131に結合するバイスペシフィック抗体
|
KR20240049296A
(ko)
|
2021-08-27 |
2024-04-16 |
제넨테크, 인크. |
타우 병증을 치료하는 방법
|
TW202325727A
(zh)
|
2021-08-30 |
2023-07-01 |
美商建南德克公司 |
抗聚泛素多特異性抗體
|
CA3230737A1
(en)
|
2021-09-03 |
2023-03-09 |
Toray Industries, Inc. |
Pharmaceutical composition for cancer treatment and/or prevention
|
US20230109496A1
(en)
|
2021-09-06 |
2023-04-06 |
Genmab B.V. |
Antibodies capable of binding to cd27, variants thereof and uses thereof
|
AU2022343729A1
(en)
|
2021-09-09 |
2024-03-21 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products using pd-1 talen knockdown
|
AU2022347380A1
(en)
|
2021-09-15 |
2024-04-11 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer
|
WO2023041717A1
(en)
|
2021-09-16 |
2023-03-23 |
Aboleris Pharma |
Anti-human cd45rc binding domains and uses thereof
|
CA3232223A1
(en)
|
2021-09-17 |
2023-03-23 |
Ying Fu |
Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
|
CA3232700A1
(en)
|
2021-09-24 |
2023-03-30 |
Rafael CUBAS |
Expansion processes and agents for tumor infiltrating lymphocytes
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法
|
WO2023051663A1
(zh)
|
2021-09-30 |
2023-04-06 |
百奥泰生物制药股份有限公司 |
抗b7-h3抗体及其应用
|
CN118159294A
(zh)
|
2021-10-05 |
2024-06-07 |
葛兰素史密斯克莱知识产权发展有限公司 |
用于治疗癌症的联合疗法
|
WO2023057946A1
(en)
|
2021-10-07 |
2023-04-13 |
Avacta Life Sciences Limited |
Serum half-life extended pd-l1 binding polypeptides
|
TW202334196A
(zh)
|
2021-10-07 |
2023-09-01 |
英商阿法克塔生命科學有限公司 |
Pd-l1結合多肽
|
AR127269A1
(es)
|
2021-10-08 |
2024-01-03 |
Chugai Pharmaceutical Co Ltd |
Formulación de anticuerpo anti-hla-dq2.5
|
WO2023064958A1
(en)
|
2021-10-15 |
2023-04-20 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
|
TW202330041A
(zh)
|
2021-10-18 |
2023-08-01 |
日商第一三共股份有限公司 |
抗cd37抗體-藥物結合物
|
AR127482A1
(es)
|
2021-10-27 |
2024-01-31 |
Iovance Biotherapeutics Inc |
Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente
|
TW202342095A
(zh)
|
2021-11-05 |
2023-11-01 |
英商阿斯特捷利康英國股份有限公司 |
用於治療和預防covid—19之組成物
|
AU2022379952A1
(en)
|
2021-11-05 |
2024-05-16 |
American Diagnostics & Therapy, Llc (Adxrx) |
Monoclonal antibodies against carcinoembryonic antigens, and their uses
|
WO2023081434A2
(en)
|
2021-11-07 |
2023-05-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
CA3237410A1
(en)
|
2021-11-10 |
2023-05-19 |
Friedrich Graf Finck VON FINCKENSTEIN |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
WO2023091887A1
(en)
|
2021-11-16 |
2023-05-25 |
Genentech, Inc. |
Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab
|
TW202334202A
(zh)
|
2021-11-16 |
2023-09-01 |
瑞士商Ac免疫有限公司 |
用於治療和診斷的新分子
|
WO2023089527A1
(en)
|
2021-11-18 |
2023-05-25 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and parp1 selective inhibitor
|
EP4186529A1
(en)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
CA3238627A1
(en)
|
2021-11-25 |
2023-06-01 |
Christine Kohler |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
TW202334238A
(zh)
|
2021-11-30 |
2023-09-01 |
日商第一三共股份有限公司 |
蛋白酶分解性遮蔽抗體
|
WO2023110937A1
(en)
|
2021-12-14 |
2023-06-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling
|
CA3240565A1
(en)
|
2021-12-17 |
2023-06-22 |
Wenfeng Xu |
Anti-ox40 antibodies and methods of use
|
CA3240585A1
(en)
|
2021-12-17 |
2023-06-22 |
Wenfeng Xu |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
TW202333800A
(zh)
|
2021-12-28 |
2023-09-01 |
英商阿斯特捷利康英國股份有限公司 |
抗體-藥物結合物及rasg12c抑制劑之組合
|
CA3240724A1
(en)
|
2021-12-28 |
2023-07-06 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and atr inhibitor
|
WO2023131901A1
(en)
|
2022-01-07 |
2023-07-13 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
WO2023139292A1
(en)
|
2022-01-24 |
2023-07-27 |
Cambridge Enterprise Limited |
Tau therapy
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023147486A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
WO2023144303A1
(en)
|
2022-01-31 |
2023-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Cd38 as a biomarker and biotarget in t-cell lymphomas
|
WO2023154824A1
(en)
|
2022-02-10 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that broadly target coronaviruses
|
TW202342519A
(zh)
|
2022-02-16 |
2023-11-01 |
瑞士商Ac 免疫有限公司 |
人源化抗tdp-43結合分子及其用途
|
TW202342520A
(zh)
|
2022-02-18 |
2023-11-01 |
美商樂天醫藥生技股份有限公司 |
抗計畫性死亡配體1(pd—l1)抗體分子、編碼多核苷酸及使用方法
|
WO2023161879A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for fibroblast activation protein-expressing cells
|
WO2023161874A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for c-c chemokine receptor 2-expressing cells
|
WO2023161881A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for ccr2-expressing cells
|
WO2023161876A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for cxcr3-expressing cells
|
WO2023161877A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for integrin avb6-expressing cells
|
WO2023161878A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for folate receptor-expressing cells
|
WO2023161875A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for prostate specific membrane antigen-expressing cells
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2023178192A1
(en)
|
2022-03-15 |
2023-09-21 |
Compugen Ltd. |
Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
|
WO2023175483A1
(en)
|
2022-03-16 |
2023-09-21 |
Astrazeneca Uk Limited |
A scoring method for an anti-trop2 antibody‑drug conjugate therapy
|
US20240103010A1
(en)
|
2022-03-18 |
2024-03-28 |
Compugen Ltd. |
Pvrl2 and/or pvrig as biomarkers for treatment
|
WO2023180353A1
(en)
|
2022-03-23 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023192827A1
(en)
|
2022-03-26 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies to hiv-1 env and their use
|
WO2023192881A1
(en)
|
2022-03-28 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
WO2023187657A1
(en)
|
2022-03-30 |
2023-10-05 |
Novartis Ag |
Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023196877A1
(en)
|
2022-04-06 |
2023-10-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
WO2023198648A1
(en)
|
2022-04-11 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t-cell malignancies
|
WO2023201299A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
JP2024517042A
(ja)
|
2022-04-13 |
2024-04-19 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd20/抗cd3二重特異性抗体の薬学的組成物及び使用方法
|
WO2023201369A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
WO2023198874A1
(en)
|
2022-04-15 |
2023-10-19 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of t cell-lymphomas
|
WO2023203177A1
(en)
|
2022-04-20 |
2023-10-26 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
|
TW202400140A
(zh)
|
2022-04-27 |
2024-01-01 |
日商第一三共股份有限公司 |
抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合
|
WO2023212304A1
(en)
|
2022-04-29 |
2023-11-02 |
23Andme, Inc. |
Antigen binding proteins
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
TW202406934A
(zh)
|
2022-05-03 |
2024-02-16 |
美商建南德克公司 |
抗Ly6E抗體、免疫結合物及其用途
|
WO2023220608A1
(en)
|
2022-05-10 |
2023-11-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
TW202400650A
(zh)
|
2022-05-11 |
2024-01-01 |
日商第一三共股份有限公司 |
抗體與cd47抑制劑之組合
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
WO2023222886A1
(en)
|
2022-05-20 |
2023-11-23 |
Depth Charge Ltd |
Antibody-cytokine fusion proteins
|
WO2023228095A1
(en)
|
2022-05-24 |
2023-11-30 |
Daiichi Sankyo Company, Limited |
Dosage regimen of an anti-cdh6 antibody-drug conjugate
|
WO2023235699A1
(en)
|
2022-05-31 |
2023-12-07 |
Jounce Therapeutics, Inc. |
Antibodies to lilrb4 and uses thereof
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023237706A2
(en)
|
2022-06-08 |
2023-12-14 |
Institute For Research In Biomedicine (Irb) |
Cross-specific antibodies, uses and methods for discovery thereof
|
WO2024003310A1
(en)
|
2022-06-30 |
2024-01-04 |
Institut National de la Santé et de la Recherche Médicale |
Methods for the diagnosis and treatment of acute lymphoblastic leukemia
|
WO2024011114A1
(en)
|
2022-07-06 |
2024-01-11 |
Iovance Biotherapeutics, Inc. |
Devices and processes for automated production of tumor infiltrating lymphocytes
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US20240132622A1
(en)
|
2022-07-22 |
2024-04-25 |
Bristol-Myers Squibb Company |
Antibodies Binding to Human PAD4 and Uses Thereof
|
WO2024018046A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Garp as a biomarker and biotarget in t-cell malignancies
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024026496A1
(en)
|
2022-07-28 |
2024-02-01 |
Compugen Ltd. |
Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodies
|
WO2024023750A1
(en)
|
2022-07-28 |
2024-02-01 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
|
WO2024023283A1
(en)
|
2022-07-29 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
WO2024028731A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Transferrin receptor binding proteins for treating brain tumors
|
WO2024028732A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Cd98 binding constructs for treating brain tumors
|
WO2024031032A1
(en)
|
2022-08-05 |
2024-02-08 |
Bristol-Myers Squibb Company |
Anti-ctla-4 antibodies for treatment of kras mutant cancers
|
WO2024037633A2
(en)
|
2022-08-19 |
2024-02-22 |
Evive Biotechnology (Shanghai) Ltd |
Formulations comprising g-csf and uses thereof
|
WO2024042112A1
(en)
|
2022-08-25 |
2024-02-29 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins and uses thereof
|
WO2024044675A1
(en)
|
2022-08-25 |
2024-02-29 |
Beigene, Ltd. |
Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies
|
WO2024044779A2
(en)
|
2022-08-26 |
2024-02-29 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
WO2024054929A1
(en)
|
2022-09-07 |
2024-03-14 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024056862A1
(en)
|
2022-09-15 |
2024-03-21 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
|
WO2024064826A1
(en)
|
2022-09-22 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
WO2024079192A1
(en)
|
2022-10-12 |
2024-04-18 |
Institut National de la Santé et de la Recherche Médicale |
Cd81 as a biomarker and biotarget in t-cell malignancies
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
WO2024098027A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
WO2024097741A1
(en)
|
2022-11-04 |
2024-05-10 |
Gilead Sciences, Inc. |
Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
WO2024100200A1
(en)
|
2022-11-09 |
2024-05-16 |
Cis Pharma Ag |
Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
|
WO2024107752A2
(en)
|
2022-11-15 |
2024-05-23 |
Onestone Therapeutics Llc |
Compositions and methods for immunomodulatory bifunctional fusion molecules
|
WO2024108053A1
(en)
|
2022-11-17 |
2024-05-23 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
WO2024112571A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
WO2024112711A2
(en)
|
2022-11-21 |
2024-05-30 |
Iovance Biotherapeutics, Inc. |
Methods for assessing proliferation potency of gene-edited t cells
|
WO2024110905A1
(en)
|
2022-11-24 |
2024-05-30 |
Beigene, Ltd. |
Anti-cea antibody drug conjugates and methods of use
|
WO2024116094A1
(en)
|
2022-11-30 |
2024-06-06 |
Daiichi Sankyo Company, Limited |
Combination of antibody-drug conjugates and dnmt inhibitors
|